Current Advances in Detection and Treatment of Babesiosis by Mosqueda, J et al.
1504  Current Medicinal Chemistry, 2012, 19, 1504-1518   
 
 
Current Advances in Detection and Treatment of Babesiosis 
J. Mosqueda*, A. Olvera-Ramírez, G. Aguilar-Tipacamú and G.J. Cantó 
C.A. Salud Animal y Microbiología Ambiental. Facultad de Ciencias Naturales, Universidad Autónoma de Querétaro, Mexico 
Abstract: Babesiosis is a disease with a world-wide distribution affecting many species of mammals principally cattle and man. The 
major  impact  occurs  in  the  cattle  industry  where bovine  babesiosis  has had  a huge  economic effect  due  to  loss of  meat  and  beef 
production of infected animals and death. Nowadays to those costs there must be added the high cost of tick control, disease detection, 
prevention and treatment. In almost a century and a quarter since the first report of the disease, the truth is: there is no a safe and efficient 
vaccine  available,  there  are  limited  chemotherapeutic  choices  and  few  low-cost,  reliable  and  fast  detection  methods.  Detection  and 
treatment of babesiosis are important tools to control babesiosis. Microscopy detection methods are still the cheapest and fastest methods 
used  to  identify  Babesia  parasites  although  their  sensitivity  and  specificity  are  limited.  Newer  immunological  methods  are  being 
developed and they offer faster, more sensitive and more specific options to conventional methods, although the direct immunological 
diagnoses  of  parasite  antigens  in  host  tissues  are  still  missing.  Detection  methods  based  on  nucleic  acid  identification  and  their 
amplification are the most sensitive and reliable techniques available today; importantly, most of those methodologies were developed 
before the genomics and bioinformatics era, which leaves ample room for optimization. For years, babesiosis treatment has been based on 
the use of very few drugs like imidocarb or diminazene aceturate. Recently, several pharmacological compounds were developed and 
evaluated, offering new options to control the disease. With the complete sequence of the Babesia bovis genome and the B. bigemina 
genome project in progress, the post-genomic era brings a new light on the development of diagnosis methods and new chemotherapy 
targets. In this review, we will present the current advances in detection and treatment of babesiosis in cattle and other animals, with 
additional reference to several apicomplexan parasites. 
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1. INTRODUCTION 
Babesiosis is a tick-transmitted disease caused by protozoans of 
the genus Babesia and it is characterized by haemolytic anemia and 
fever, with occasional hemoglobinuria and death[1]. It is a disease 
with a world-wide distribution affecting many species of mammals 
with a major impact on cattle and man [2, 3]. With the complete 
sequence of  the Babesia bovis genome [4], the post-genomic  era 
brings  a  new  light  on  the  development  of  diagnosis  methods, 
improved vaccines and new chemotherapy targets.  
Babesiosis  was  first  reported  in  1888  by  Viktor  Babes  in 
Romania  who  detected  the  presence  of  round,  intra-erythrocytic 
bodies in the blood of infected cattle [5]. Babes failed to report the 
presence of ticks in sick cattle but in 1893, Theobald Smith and 
Frederick Kilborne of the Bureau of Animal Industry of the United 
States, published their results of a series of experiments demons-
trating  that  the  southern  cattle  tick  Boophilus  (Rhipicephalus) 
annulatus  dropping  from  infected  cattle,  were  responsible  for 
transmitting a disease called the tick fever to susceptible cattle [6]. 
This observation is considered to be the first to describe a vector 
arthropod as the carrier of disease. The observations of Smith and 
Kilborne  were  strengthened  by  Cooper  Curtice’s  own  hypothesis 
that eliminating the cattle tick would eliminate the disease, and they 
were the basis for the establishment of a tick eradication program, 
which culminated with the  eradication of the southern cattle tick 
and  babesiosis  from  the  United  States  territory  in  1943  [7]. 
Although  there  is  a  quarantine  zone  in  the  southern  border  with 
Mexico with  sporadic outbreaks of ticks  and babesiosis [8], it is 
considered the only successful eradication tick program ever.  
Parasites of the genus Babesia infect a wide variety of domestic 
and wild mammals as well as man [9]. However, the major impact 
occurs in the cattle industry and the species affecting bovines are 
the  most  studied,  including  Babesia  bovis,  B.  bigemina  and  B. 
divergens [2]. Since the times of Babes, Smith and Kilborne, bovine 
babesiosis has had a huge economic impact due to loss of meat and 
beef production of infected animals and death. Nowadays to those 
costs  there  must  be  added  the  high  cost  of  tick  control,  disease 
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detection, prevention and treatment [10]. Moreover an indirect and 
underestimated  cost  of  the  disease  is  related  with  the  refusal  of 
cattle farmers in endemic areas to improve the production of beef 
and milk in their herds by introducing beef or milk-producing, pure-
breed animals, most of them from tick-free areas, because they will 
present  an  acute  form  of  the  disease  and  many  will  die  in  the 
following weeks to their arrival. The consequence is that the quality 
of  cattle  in  endemic  areas  remains  low,  therefore  impeding  the 
development of the cattle industry and the wellbeing of producers 
and their families [11]. In almost a century and a quarter since the 
first report of the disease, the truth is: there is no a safe and efficient 
vaccine available, there are limited chemotherapeutic choices and 
few low-cost, reliable and fast detection methods. Because of the 
importance of bovine babesiosis, here we will present the current 
advances in detection and treatment of babesiosis in cattle and other 
animals,  with  additional  reference  to  several  apicomplexan 
parasites.  
2. DETECTION METHODS OF BABESIOSIS 
The  diagnosis  of  bovine  babesiosis  is  an  important  tool  to 
control  and  prevent  the  dissemination  of  the  disease.  During  the 
acute  stage  of  the  disease  the  number  of  parasites  inside  the 
erythrocytes  increases  in  such  a  way  that  they  can  be  detected 
microscopically, however, in chronically infected animals where a 
subclinical form of the disease occurs, this method is useless and 
other, more sophisticated methods must be employed.  
2.1. Microscopy Detection Methods 
Babesia parasites have a complex life cycle as described in Fig. 
(1).  Identification  of  the  different  stages  of  the  parasite  in 
mammalian  or  arthropod  host  tissues  can  be  used  for  direct 
diagnosis purposes. 
2.1.1. Thin and Thick Blood Smears 
Vicktor Babes was the first to identify B. bovis on thin blood 
smears of infected cattle [5]. Theobald Smith was also looking for 
the  causative  agent  of  cattle  fever  for  several  years  but  he 
consistently  failed;  the  reason,  he  was  looking  into  blood  from 
chronically infected cattle. It was until an acute case came across to 
him that he could identify the intraerythrocytic corpuscles, in this 
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case B. bigemina [12]. Thin blood smears were the first method to 
detect  Babesia  parasites  in  clinical  samples,  a  method  still  used 
today  very  effectively  in  most  diagnostic  laboratories.  Blood  is 
usually collected, combined with an anticoagulant and smeared on a 
glass slide, air-dried, fixed with methanol, and stained with Giemsa 
or  a  similar  stain  for  several  minutes.  The  slide  is  then  washed 
thoroughly and dried. Intraerythrocytic parasites are observed under 
a microscope using a 100X objective and a drop of immersion oil. 
For  B.  bigemina,  paired  merozoites  measure  2.5-3.5  µm  of 
diameter; B. bovis merozoites measure 1.5-2 µm of diameter and B. 
divergens merozoites measure 1.5-0.4 µm. They can be detected for 
up to one infected erythrocyte per ten thousand cells, requiring the 
analysis of 100-200 fields, the equivalent to 0.5 µl of blood [13, 
14]. It is easy to do and inexpensive but requires an experienced 
microscopist  to  differentiate  species  and  is  reliable  only  if  the 
amount  of  parasites  in  the  blood  is  high  enough  to  be  detected, 
which is usually only possible during acute cases. Special attention 
must be paid to the source of the blood; peripheral blood is useful 
only for species like B. bigemina, B. divergens, or B. gibsoni, which 
do not adhere  to the vascular  endothelium. Some  species  like B. 
bovis  or  B.  canis  adhere  to  endothelial  cells  [15,  16]  and  their 
diagnosis using this method is feasible if the blood sample is taken 
directly from a blood capillary from the ear or the skin of the tail, 
compared with peripheral blood taken from the jugular or caudal 
veins, since capillary blood contains a higher percentage of infected 
erythrocytes  for  these  species.  The  observation  of  paired 
intraerythrocytic merozoites is indicative of infection but there are 
other  stages  of  the  parasite  like  the  trophozoites,  which  present 
different forms and sizes depending on the species, and these make 
their detection difficult and time-consuming (Fig. 2A-C) [17].  
Another  technique  developed  to  detect  low  levels  of 
parasitemia, especially in cases where B. bovis is involved, is based 
on thick smears of infected blood stained with Giemsa [13, 18]. For 
this technique, in order to obtain good results, a small drop of blood 
is placed in the center of the slide and it is fixed by heat, without 
smearing it, then it is stained routinely, washing it carefully to avoid 
losing the tissue while the excess of stain is removed. Once it has 
been dried, it can be observed with a microscope, similarly as the 
thin smear [19]. The advantage of the thick smear is that a large 
amount of erythrocytes is analyzed in a reduced amount of space, 
therefore the probability of finding infected cells is ten times higher 
than in the thin smear [18]. The method is usually recommended 
when  B.  bovis  infections  are  suspected  or  when  a  subclinical 
disease  occurs.  This  method  relies  on  a  very  experienced 
microscopist who must identify the Babesia-infected cells among a 
mass of conglomerated erythrocytes.  
2.1.2. Brain Smears 
When  a  bovine  has  died  and  it  is  presumed  to  be  from 
babesiosis caused by B. bovis due to presence of nervous clinical 
signs, identification of the parasite can be done by brain smears. In 
this case, a small sample of grey matter of the cerebral cortex is 
placed on a slide and the tissue is smeared using another slide. The 
brain tissue is fixed and stained as mentioned above. The diagnosis 
is based upon observation of brain capillaries filled with infected 
erythrocytes  [1].  Almost  one  hundred  percent  of  erythrocytes 
present in the brain capillaries are infected (Fig. 2E) [20]. Smears 
of other organs as the kidney or liver can also be carried out with 
good results. 
2.1.3. Haemolymph Smears 
As a tick-transmitted pathogen, Babesia parasites infect several 
tick tissues. Immediately after repletion with a blood meal, the tick 
acquires  intracellular  parasites,  which  soon  escape  from  the 
erythrocytes and remain in the gut lumen for a short period of time. 
Sexual reproduction occurs and infective diploid cells penetrate the 
midgut cells of the tick and transform to motile stages called kinetes 
after  72  h  post-repletion  [21].  Kinetes,  are  motile  stages  of  the 
parasite, which reach the haemolymph of the tick and infect several 
organs including the ovary of mated females. A good approach to 
identify  adult  females  infected  with  Babesia  is  detecting  kinete 
stages in the haemolymph by performing the haemolymph test. For 
this technique, a leg of the tick is cut with small scissors to obtain a 
drop of haemolymph, which is placed on a glass slide. Usually the 
drop is too small to be smeared so it is let dry, fixed and stained as a 
regular blood smear. The diagnosis is based on the observation of 
the kinetes, which have a vermicular shape and are usually 14.3-
16.9 µ long by 2.8-3.4 µ wide, depending on the species (Fig. 2D) 
[22,  23].  It  is  very  difficult  to  differentiate  species  by  the 
haemolymph test. Based on the biological cycle, kinetes first appear 
72 h after engorgement and remain in the haemolymph until the 
female tick dies, with maximum kinete presence at days 5-6 post 
repletion [21]. It has been suggested that Rhipicephalus (Boophilus) 
ticks  have  been  adapted  to  start  laying  their  eggs  before  kinetes 
reach the ovary and invade the developing embryos; the first eggs 
are laid at 72 h post repletion and the first infected eggs appear 92 h 
post repletion. By laying some of the eggs before they are infected 
by the parasite, female ticks ensure a percentage of their progeny to 
be Babesia-free [24]. The haemolymph test requires an experienced 
microscopist  since  female  ticks  collected  from  cattle  in  endemic 
areas have a very low amount of kinetes.  
2.2. Immunological Methods 
2.2.1. Indirect Fluorescent Antibody Test (IFAT) 
When the number of Babesia parasites in the blood is too low to 
be  detected,  searching  for  antibodies  against  proteins  of  blood 
stages has proven to be a reliable tool to identify infected carriers or 
previously exposed animals. The IFAT was first described by Ristic 
and  Sibinovic  in  1964  to  detect  antibodies  against  B.  caballi  in 
chronically infected horses [25]. Since then, it has been adapted to 
all  Babesia  species  and  has  a  good  level  of  specificity  and 
sensitivity [26-31]. The IFAT is based on the recognition of parasite 
antigens  by  serum  antibodies  in  the  blood  of  the  tested  animal. 
Bound antibodies are detected by a fluorochrome-labelled antibody 
anti-Ig  (secondary  antibody).  Antigen  preparation  consist  of 
intraerythrocytic  merozoites  grown  in  culture  or  obtained  from 
infected  blood  removed  of  plasma  and  white  cells,  so  that 
erythrocytes with a high level of parasitemia (>7%), usually mixed 
with  5%  bovine  serum  albumin  or  another  soluble  protein,  are 
smeared on a glass slide. Once the smears dry, they are wrapped 
individually and stored at -70°C and in this way they can last for 
several years. When the antigen is going to be used, the slides are 
thawed,  desiccated  and  fixed  with  acetone,  which  removes  the 
haemoglobin and permeates the cell [32]. IFAT consists of a series 
of  incubation  and  washing  steps,  first  the  serum  to  be  tested  is 
diluted 1:80 and after an incubation period the unbound antibody is 
removed  by  washing.  A  secondary  antibody  anti-bovine  IgG 
conjugated  with  a  fluorochrome  is  used  to  identify  bound 
antibodies.  After  a  second  round  of  washing  steps,  the  smear  is 
dried and analyzed with a fluorescence microscope using specific 
filters  for  the  fluorochrome.  Positive  results  depend  on  the 
observation of fluorescent parasites indicating the presence of anti-
Babesia antibodies in the tested serum (Fig. 2F). IFAT is easy to do 
but requires a good quality antigen, which is difficult to obtain. It 
also  requires  an  experienced  microscopist  and  a  fluorescence 
microscope. It can discriminate between Babesia species although 
some cross-reaction problems have been reported [33]. Historically, 
Fluorescein  Isothiocyanate  (FITC) has been used  as the standard 
fluorochrome  for  IFAT,  however,  newer  fluorescent  dyes  like 
Alexa-488  (Invitrogen,  USA)  or  Dylight-488  (Jackson 
ImmunoResearch, USA) offer better options due to their improved 
photostability and brightness, and a wider pH range [11].  
Detection of anti-Babesia antibodies from wildlife species can 
be  achieved  by  using  a  dye-conjugated  Protein  G  or  A  [34]. 1506    Current Medicinal Chemistry,  2012 Vol. 19, No. 10  Mosqueda et al. 
Originally, Protein G and  A  are bacterial proteins that bind with 
high  affinity  to  the  Fc  region  of  several  classes  of  antibodies. 
Commercial,  recombinant  proteins  are  available  and  they  are 
engineered so that the Fab binding domain and the albumin domain 
present  in  the  native  proteins  were  removed,  leaving  only  their 
high-affinity Fc domain. For example, antibodies from white-tailed 
deer (Odocoileus virginianus) against B. bovis or B. bigemina have 
been detected using Protein G coupled with FITC or Alexa-488 [35, 
36]. Since Protein G and A differ in their affinity to bind antibodies 
from  different  species,  the  evaluation  and  selection  of  the 
appropriate protein are necessary. 
2.2.2. Enzyme-Linked Immunosorbent Assay (ELISA) 
When a large number of serum samples is processed, the IFAT 
test becomes time-consuming and not very effective; this is mainly 
because  each  sample  must  be  analyzed  at  one  time  by  the 
diagnostician  and reading each  sample may take several minutes 
[37].  Other  methods  based  on  automation  like  ELISA  are  very 
useful. ELISA has  the  advantage of non-subjectivity,  capacity to 
read  a  large  number  of  samples  easily  and  presents  higher 
specificity than the IFAT. There are several ELISA versions for the 
detection  of  several  Babesia  species  including  B.  bovis,  B. 
bigemina,  B.  divergens,  B.  caballi,  B.  canis,  B.  gibsoni,  and  B. 
microti [32, 38-40]. This ELISA  method was initially performed 
using  purified  crude  antigen  from  infected  blood,  but  the  cross-
reactivity with serum proteins was very high [13]. Recent ELISA 
methods include the use of recombinant antigens and monoclonal 
antibodies,  thus  increasing  specificity  and  diminishing  unspecific 
binding and signal. Modern biotechnology allows the expression of 
antigenic pathogen proteins, which can be bound on ELISA wells 
and used to evaluate the presence of anti-babesia antibodies using 
an anti-IgG conjugated with an enzyme, usually peroxidase [41-44]. 
A common problem observed in bovine babesiosis diagnosis with 
this indirect ELISA is the fact that recombinant proteins, especially 
those  expressed  in  bacteria  are  often  co-purified  with  bacteria 
proteins, to which bovine serum reacts strongly, thus giving high 
background signal, affecting the interpretation and standardization 
protocols.  An  approach  to  overcome  this  problem  is  to  use  a 
monoclonal  antibody  against  a  conserved  epitope  in  the  target 
protein  and implement  a competitive ELISA  (cELISA) format in 
which unbound antigen is recognized by the monoclonal antibody 
and this is detected by a labelled Anti mouse-IgG antibody. In this 
way, the signal observed is the result of the lack of specific bovine 
antibodies bound to the recombinant protein, thus avoiding noise 
signal due to unspecific binding. cELISA has been developed for B. 
bovis, B. bigemina and B. caballi and their use has been validated in 
several diagnostic laboratories around the world [45-48].  
2.2.3. Immunochromatography Test (ICT) 
The immunochromatographic test is a rapid diagnostic device 
that detects antibodies against a specific antigen in a small amount 
of serum by means of specific antibody and a recombinant antigen 
both  impregnated  on  a  nitrocellulose  membrane-based  test  strip 
[49]. ICT is very convenient because it is very easy to perform and 
read, therefore does not require a trained technician; it does not use 
any special equipment, so it can be implemented in the field and it 
has a low cost comparable with other techniques; it is a fast test 
taking only ten to fifteen minutes to complete and it is very stable 
under different temperatures [50]. All of these  are very powerful 
reasons to consider the ICT the immunological diagnostics method 
of the future, especially for diseases like babesiosis where a rapid, 
easy  to  read  assay  is  very  much  needed  under  field  situations 
particularly  in  developing  countries  where  equipment  and 
electricity are limiting. ICT has been developed for Babesia bovis, 
B. bigemina, B. caballi, B. gibsoni and B. microti [51-55]. All of 
them use rabbit polyclonal antibodies as the base for the test. These 
tests use recombinant antigens like the merozoite surface antigen 2 
(MSA-2) for B. bovis; the rhoptry associated protein 1 (RAP-1) for 
B. bigemina; a 48 kDa rhoptry protein for B. caballi (Bc48); the 
P50  antigen  of  B.  gibsoni  as  well  as  the  secreted  antigen  1 
(BgSA1); and a novel secreted antigen 1 for B. microti (BmSA1). 
The concordances compared with standard methods like ELISA and 
IFAT  have  been  evaluated  for  B.  bovis  (92.5  and  90.3%, 
respectively), B. bigemina (96.8  and 92.5%,  respectively)  and B. 
gibsoni (100 and 85.7%, respectively). Concordance with ELISA 
has  been  determined  for  B.  caballi  (91.8%).  Combined  ICT 
designed  to  detect  different  species  in  the  same  assay  has  been 
developed for B. bigemina/B bovis and for B. caballi/Thelieria equi 
[55,  56].  The  implementation  of  tests  using  highly  specific 
monoclonal antibodies, and those designed to identify the parasites 
directly  from  a  blood  sample,  which  are  very  much  needed  to 
diagnose acute babesiosis, have yet to be developed; although there 
is hope since there are already commercial tests for malaria [57]. To 
date, ICT not yet commercially available in any country.  
2.3. Molecular Methods 
Immunological  methods  to  detect Babesia  parasites  have  the 
disadvantage  of  relying  on  the  presence  of  specific  antibodies 
against those parasites, which may take days or weeks to develop in 
an infected animal or they are present for months after the infection 
has  disappeared,  making  their  usefulness  very  limited  in  acute 
disease cases, vaccinated animals or cleared-by-treatment animals. 
Molecular methods aimed to detect nucleic acids have been very 
useful  when  immunological  methods  do  not  work.  Detecting 
nucleic acids is an indirect way of detecting the parasite so they are 
still  considered  indirect  methods.  However,  the  sensitivity  and 
specificity of these methods are very high and over the past years 
many different approaches have been developed to detect Babesia 
species in their hosts and their vectors.  
2.3.1. DNA Probes 
Deoxyribonucleic acid probes were the first method developed 
to detect babesial DNA from parasitized blood. For this, DNA is 
isolated, purified and cloned while adding a marker, which initially 
was radioactive. The marked single stranded DNA is then used to 
hybridize  to  DNA  present  in  a  tissue,  or  a  membrane.  The  high 
specificity  of  DNA  alignment  allows  only  the  hybridization  to 
complementary DNA, thus recognition of the desired sequence and 
a  very  specific  diagnosis.  Detection  is  carried  out  by 
autoradiography,  chemiluminescence  or  a  colorimetric  substrate. 
McLaughlin et al., in 1986 developed a cloned B. bovis radioactive 
probe which was used by dot blot hybridization to effectively detect 
100 pg of B. bovis DNA, estimated to be equal to DNA present in 
50 microliters of 1 in 10
5 infected erythrocytes [58]. Buening et al., 
described a radioactive repetitive DNA probe, which detected 10 pg 
of B. bigemina DNA and as few as 150 infected erythrocytes [59]. 
Radioactive probes were developed for other species including B. 
caballi [60] but the hazard of radio-labeled material, short life of 
radioactivity  and  high  maintenance  costs  made  them  difficult  to 
establish  as  standard  detection  methods.  Soon  non-radioactive 
probes  were  designed  using  chemi-luminescence  or  colorimetric 
approaches  [61,  62].  DNA  probes  have  also  been  used  to  detect 
Babesia  parasites  in  tick  tissues  and  their  high  sensitivity  was 
useful for the detection of infected carriers [63, 64]. However, this 
methodology takes several days to complete, requires a specialized 
technician  and  continuous  labeling  of  the  probes;  all  these  were 
disadvantages against newer methods developed afterwards.  
2.3.2. Polymerase Chain Reaction (PCR) 
The first descriptions of the polymerase chain reaction to detect 
Babesia were reported in 1992 for B. bovis [65], B. bigemina [66] 
and B. microti [67]. An adaptation of the technique is the nested 
polymerase  chain  reaction  (nested  PCR),  a  format  in  which  two 
pairs  of  primers  are  used  in  two  successive  PCR  amplifications 
where  the  second  pair  is  intended  to  amplify  a  secondary  target 
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for the detection of carrier animals infected with B. bigemina and B. 
microti and the sensitivity has been reported to be as low as one and 
three infected erythrocytes, respectively [66, 67]. When nested PCR 
has been combined with labelled probes, the sensitivity increases 
several logs of magnitude. For example, nested PCR for B. bovis 
was reported to detect 1 parasite in 10
6 erythrocytes, but when the 
resulted  amplified  product  was  detected  with  a  DNA  probe,  the 
sensitivity increased to 1 in 10
9 [68]. Nested PCR is a very sensitive 
tool but it is more expensive, takes more time and the risk of self-
contamination is higher than the one-step PCR protocol. There have 
been other protocols in which a single-step PCR has been used with 
good results. For B. bovis, a one-step PCR combined with a labelled 
probe was able to detect 10 parasitized erythrocytes in 500 µl of 
blood  [65];  a  similar  methodology  was  developed  for  B.  caballi 
[69].  All  these  protocols  have  a  high  degree  of  sensitivity  and 
specificity  yet,  they  are  time  consuming,  expensive  and  require 
trained personnel, plus the disadvantages of the labelled probes as 
commented  earlier.  More  recent  protocols  have  been  published 
based  on  single  or  nested  steps  without  the  use  of  hybridization 
steps  and  with  good  levels  of  sensitivity.  A  one-step  PCR  was 
developed for B. bigemina with a level of detection of 2 parasites in 
10
8 erythrocytes [70]. B. gibsoni was detected in 1.5 µl of blood 
with a parasitemia of 2 in 10
9, and B. ovis was detected in a blood 
sample with a parasitemia 1 in 10
8 [71, 72]. Similar methodologies 
have  been  described  for  B.  caballi  [73]  and  B.  canis  subspecies 
[74]. One point worth to mention is that many of the PCR protocols 
reviewed  here  were  published  before  the  genomics  and 
bioinformatics era, thus primer design, including absence of primer 
dimmer or loop formation, BLAST analysis, sequence conservation 
and  an  appropriate  thermocycler  protocol  were  not  considered, 
which means the primers and the protocols could still be optimized, 
these  aspects  may  be  considered  when  implementing  these 
methodologies in diagnostic laboratories around the world. 
2.3.3 Reverse Line Blot Hybridization (RLB) 
When  multiple  genera,  species  or  strains  are  going  to  be 
detected in a sample of blood or tissue, there is a better option than 
PCR.  Reverse  line  blot  hybridization  is  a  technique  initially 
developed for the diagnosis of sickle cell anaemia [75], then it was 
used  to  detect  multiple  serotypes  of  Streptoccoci  [76]  and  three 
genotypes  of  Borrelia  [77].  RLB  consists  of  specific 
oligonucleotides  covalently  bound  to  a  membrane  by  a  N-
(trifluoracetamidohexyl-cyanoethyl,N,N-diisopropyl  phos- 
phoramidite  [TFA])-C6  amino  linker.  The  oligonucleotides  are 
applied  with  a  miniblotter  in  an  aligned  format.  PCR  amplified 
products  labelled  with  biotin,  are  then  hybridized  using  the 
miniblotter  but  in  an  alignment  perpendicular  to  the 
oligonucleotides;  in  this  way  it  is  ensured  that  all  the  amplified 
samples are exposed to each specific oligonucleotide. After a series 
of stringent washes, the membrane is incubated with a streptavidin-
peroxidase  conjugate  and  the  signal  is  detected  by  adding  a 
substrate using chemiluminescence. Visualization of a dot indicates 
the spot where the amplified PCR product recognized and bound 
the specific oligonucleotide [78]. This method has been used for the 
detection  of  several  species  of  Babesia  including  B.  bovis,  B. 
bigemina,  B.  divergens,  B.  major,  B.  motasi,  B.  crassa,  and  B. 
caballi, although this technique is mostly used for the  combined 
detection of different genera and species in epidemiological studies 
[79-83].  The  most  recognized  advantage  of  RLB  is  that  the 
membranes can be re-used up to 20 times, thus reducing the overall 
costs  of  the  procedure  [79].  Certainly  this  technique  is  valuable 
when several pathogens, species or strains are present in the same 
sample.  
2.3.4. Real Time PCR (RT-PCR) 
Real Time PCR is a technique that amplifies and quantifies a 
specific DNA fragment. The DNA amplified is quantified as it is 
being generated (in “real time”), therefore it determines whether a 
specific sequence is present in the sample, and it also determines 
the  number  of  copies  of  that  sequence.  RT-PCR  does  this  by 
detecting a fluorescent signal emitted during the PCR reaction as an 
indicator of the production of the sequence being generated in each 
cycle; this is opposite to what happens in during the end-point PCR, 
where the detection of the product is at the end of the reaction. RT-
PCR  has  many  advantages  over  conventional  PCR;  it  does  not 
require  post-PCR  analysis  because  the  signal  is  detected  as  it  is 
generated, therefore, it is faster and it does not generate expenses 
due  to  electrophoretic  analysis  or  photo-documentation. 
Additionally, the fact that the positive fluorescent signal is detected 
by the thermocycler, the sensitivity is higher compared with the in-
gel  analysis  of  ethidium  bromide-stained  DNA  detected  in  a 
conventional PCR, and it has been reported to be at least fourfold 
[84]. There are several formats for RT-PCR, the most common are 
based on the use of SYBR Green or TaqMan probes. The first RT-
PCR method reported for the quantification of Babesia was in 2003 
when SYBR Green was used to quantify the  transcription of the 
Babesia  bigemina  rap-1  locus  genes  [85].  Since  then  several 
protocols have been published for the quantification of B. gibsoni, 
B.  microti,  B.  bovis,  B.  bigemina,  B.  caballi,  B.  canis,  and  B. 
orientalis, [86-93]. The sensitivity of RT-PCR has been reported to 
be also higher than that of conventional PCR, for example, for B. 
bovis and B. bigemina, it was reported to detect 0.75 copies of DNA 
per  µl  of  blood  [87].  Probably  the  only  disadvantage  of  this 
methodology is the higher costs of the equipment, which usually 
doubles or triples the cost of a conventional PCR machine.  
2.3.5. Loop Mediated Isothermal Amplification (LAMP) 
LAMP  is  a  detection  method  that  amplifies  DNA  under 
isothermal  conditions with high efficiency, specificity  and speed. 
LAMP is based on the use of four primers specifically designed to 
amplify six different sequences on the same target DNA, with the 
aid of an isothermal DNA polymerase. By using four primers to 
amplify  the  same  target  sequence,  the  specificity  of  the 
amplification  in  increased,  solving  in  part  the  background 
amplification observed in most nucleic acid amplification methods. 
Because  LAMP  produces  a  large  amount  of  DNA,  it  can  be 
analysed by direct observation of; a) an intercalating fluorochrome 
like  SYBR  green,  ethidium  bromide,  etc.  [94],  b)  the  turbidity 
generated by magnesium pyrophosphate precipitation as a result of 
pyrophosphate  ion  by-product  [95],  or  c)  a  newer  colorimetric 
method using the metal  ion hydroxy naphthol blue (HNB)  as  an 
indicator. This colorimetric assay is reported to be superior to the 
existing  colorimetric  assays  for  LAMP  with  regard  to  reducing 
contamination risks and expenses [96]. Because of this, LAMP does 
not  require  of  electrophoresis  and  image  documentation  post-
analysis.  Additionally,  the  isothermal  conditions  required  for  the 
DNA  polymerase  make  the  use  of  a  thermocycler  dispensable, 
reducing overall cost and time. The sensitivity of LAMP has been 
estimated to be of a minimum of six copies of target DNA [94]. 
Babesia species have been detected by LAMP including B. gibsoni, 
B. caballi, B. bovis, B. bigemina, Babesia canis and B. orientalis 
[97-101].  It  has  also  identified  uncharacterized  Babesia  species 
infecting sheep and goats in China [102]. For Babesa bovis and B. 
bigemina  the  detection  level  was  increased  up  to  10
3  and  10
5, 
respectively  compared  with  conventional  PCR  protocols  [99]. 
Finally,  LAMP  is  a  technique  with  many  advantages  over  other 
nucleic acid-based detection methods and it may be advantageous 
in developing countries or laboratories where specialized equipment 
is absent.  
3. ANTI-BABESIA DRUGS  
Control of bovine babesiosis can be either by tick management, 
immunization,  anti-babesia  drugs  or  by  a  combination  of  these 
approaches  [103].  Chemotherapy  of  babesiosis  is  important  for 
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Table 1.  Chemical Drugs Used to Treat Babesiosis 
 
Compound  Chemical name  Babesia spp.  Dose 
 
Rout  Current use  References 
Imidocarb  3,3’-bis (2-imidazolin-2-yl)-carbanalidae  B. bovis 
B. bigemina 
B. divergens 
B. caballi 
1-3 mg kg
-1 
 
IM, SC  Yes  [105] 
Diminazene aceturate  4,4´(azoamino)dibenzamidine  B. bovis 
B. bigemina 
B. divergens 
B. caballi 
3-5 mg kg
-1  IM 
 
Yes  [105] 
Nerolidol  cis-3,7,11-Trimethyl- 
1,6,10-dodecatrien-3-ol  
 
B. bovis 
B. bigemina 
B. ovata 
B. caballi 
10µM 
25 µM 
-  On research  [110] 
Artesunate  3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydrido-3,6,9-
trymetyl-3,12-epoxy-12H-pyranol(4,4/l-1,2-
benzodioepin-10-ol hydrogen succinate 
B. bovis 
B. gibsoni  
B. caballi 
B. microti 
2.6 µM 
10 µg ml
-1 
10 mg kg
-1 
-  On research  [108] 
Triclosan  2’,4’,4’-tricloro-2’-hydroxyphenil ether  B. bovis 
B. bigemina 
B. caballi 
100µg ml
-1 
50 µg ml
-1 
-  On research  [111] 
 
Epoxomicin   α´,β´-epoxyketone  B. bovis 
B. bigemina 
B. ovata 
B. caballi 
B. microti 
10 nM 
5 nM 
0.05-0.5 mg kg
-1 
-  On research  [161] 
Gossypol  1,1’,6,6’,7,7’-hexahydroxy-5,5’-diisopropyl- 
3,3‘dimethyl [2,2’-binaphthaleneI8,8‘-dicar-
boxaldehyde. 
B. bovis  100µM  -  On research  [174] 
Atovaquone  1,4-hydroxynaphthoquinone  B. divergens  1 mg kg
-1  -  On research  [189] 
IM Intramuscular, SC Subcutaneous.  
artificially induced infections [104]. In the past, treatment of cattle 
babesiosis was less important than disease eradication, principally 
in countries were the goal was to eradicate the tick vector; however, 
chemotherapy has been important to control and prevent babesiosis 
in some areas of the world [105]. In endemic areas, sick animals 
should be treated as soon as possible with an anti-parasitic drug. 
The success of the treatment depends on early diagnosis  and the 
prompt  administration  of  effective  drugs  [106,  107].  A  large 
number of chemical compounds have been reported to be effective 
against bovine Babesia parasites. Some of them were very specific 
and effective [105, 106], but many have been withdrawn for several 
reasons  [107].  In  addition,  supportive  therapy  such  as  blood 
transfusions,  anti-inflammatory  drugs,  tick  removal,  iron 
preparations,
 dextrose, vitamins (B complex), purgatives, and fluid 
replacements, may be necessary in severe cases of babesiosis [3, 
105].  The  first  specific  drug  used  against  bovine  babesiosis  was 
trypan  blue,  which  is  a  very  effective  compound  against  B. 
bigemina infections, however, it did not have any effect on B. bovis 
and it had the disadvantage of producing discoloration of animal’s 
flesh, so it is rarely used [105]. For many years, the babesiacides: 
quinuronium  sulfate,  amicarbalide,  diminazene  aceturate  and 
imidocarb  diproprionate  were  used  against  bovine  babesiosis  in 
most  of  Europe;  however,  quinuronium  sulfate  and  amicarbilide
 
were  withdrawn  because  of  manufacturing  safety  issues,  and 
diminazene,
  which  is  widely  used  in  the  tropics  as  both  a 
babesiacide  and
  a  trypanocide,  was  withdrawn  from  Europe  for 
marketing  reasons  [3,  106];  in  addition,  the  product  was  also 
withdrawn from the market in Japan recently and is not approved 
by the Food and Drug Administration in U.S.A. [108].  
The  indiscriminate  use  of  anti-Babesia  prophylactic  agents, 
including the administration of the drug at sub lethal blood levels to 
animals, can produce the development of drug resistant parasites, a 
problem that will require the development of new drugs [106, 109]. 
New drugs with a chemotherapeutic effect against babesiosis, with 
high specificity to the parasites and low toxicity to the hosts  are 
desired  to  control  the  disease  [110,  111].  Identification  of  novel 
drug  targets  is  usually  based  upon  metabolic  pathways  and  cell 
structure [106]. Babesia spp. are Apicomplexa parasites that invade 
erythrocytes  and  multiply  asexually  with  a  reproductive  phase 
[112], which differ from other Apicomplexa that are able to invade 
and replicate within nucleated cells. However, Babesia is closely 
related  to  Plasmodium  protozoa,  which  also  proliferate  within 
erythrocytes  and  some  drugs  can  be  useful  for  both  of  these 
erythrocyte-invading parasites [106]. In addition, most members of 
the  phylum  Apicomplexa  harbor  a  semiautonomous  plastid  like 
organelle  called  apicoplast,  which  was  derived  via  secondary 
endosymbiotic events from an eukaryotic alga [113]. The apicoplast 
is  essential  for  long  term  parasite  viability  and  has  been  an 
attractive  target  for  development  of  parasiticidal  drug  therapies 
[114].  In  fact,  the  genome  of  B.  bovis  has  been  sequenced  and 
provides  a  greater  understanding  of  B.  bovis  metabolism  and 
potential  avenues for drug therapies [4].  Table 1 summarizes the 
drugs used for the treatment of bovine babesiosis, their chemical 
name, doses, administration route and references. Thus, this part of 
the review will discuss the anti-Babesia drugs, novel and in current 
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Fig. (1). The life cycle of Babesia bovis. 
A. A B. bovis sporozoite invades an erythrocyte and transforms into a trofozoite. 
B. The trofozoite in a ring shape. 
C. Two merozoites are generated from each trofozoite by binary fission. 
D. Merozoites are initially bound together resembling two pears in an acute angle. 
E. The mature merozoites separate before escaping the erythrocyte. 
F. Merozoites are liberated from the erythrocyte. Some of them will invade new erythrocytes and develop into trofozoites, while others will be picked up by 
adult ticks to continue their cycle in the invertebrate host. 
G. Sexual stages are freed from the red blood cells in the intestinal tick lumen and develop to gametocytes. 
H. The gametocytes transform into male and female gametes that form a zygote after fusion. 
I. The zygote develops into an infecting stage and penetrates the tick intestinal cells. 
J. Fission bodies form and from them motile kinetes develop. 
K. Kinetes destroy the intestinal cells, escape into the haemolymph and distribute into the different cell types and tissues, including the ovaries. 
L. In the ovary, embryo cells are infected by kinetes (transovarial transmission). 
M. When the female tick lays her eggs, the embryos are already infected. 
N. Hatched infected larvae attach to a bovine and the kinetes migrate to the salivary glands of the tick, where they form a sporoblast. 
O. Thousands of sporozoites develop from each sporoblast. 
P. Tick larvae feed from the bovine blood and the sporozoites are liberated with saliva into the animal’s circulatory system. 1510    Current Medicinal Chemistry,  2012 Vol. 19, No. 10  Mosqueda et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Babesia especies in various hosts and tissues. A) Babesia bigemina in bovine erythrocytes. Blood smear stained with Giemsa. B) Babesia bovis in 
bovine erythrocytes. Blood smear stained with Giemsa. C) Babesia microti in mouse erytrocytes. Blood smear stained with Giemsa. D) Babesia bigemina 
kinetes  in  Rhipicephalus  (Boophilus)  microplus  haemolymph.  Haemolymph  smear  stained  with  Giemsa.  E)  Babesia  bovis  in  a  bovine  brain  capillar. 
Histological section of brain tissue stained with Giemsa. F) Detection of antibodies against Babesia bigemina by the Indirect Fluorescent Antibody Test 
(IFAT). Bovine antibodies were detected by a secondary, donkey IgG anti- bovine IgG bound to Alexa-Fluor 488. Images were obtained with an objective of 
100X.  
3.1. Conventional Drugs 
3.1.1. Imidocarb 
Imidocarb is a carbanilide derivative [3,3’-bis (2-imidazolin-2-
yl)-carbanalidae] with antiprotozoal activity (Fig. 3). It is usually 
administered either  as  the dipropionate salt or  the dihydrocloride 
salt. It is the principal babesiacide used in animals, the only one that 
consistently clears the host of parasites [103, 115] and for over 20 
years,  it  has  been  used  in  the  treatment  and  prophylaxis  of 
babesiosis  and  anaplasmosis  [105,  115].  The  administration  in 
cattle  and  sheep,  is  either  by  subcutaneous  or  intramuscular 
injection [116]. Intravenous injection is not recommended due to its 
high  toxicity,  which  may  cause  death  in  a  few  minutes  [105]. 
Imidocarb is effective at a recommended dose of 1-3 mg/kg, and it 
is the drug of choice for bovine babesiosis caused by B. bigemina, 
B. bovis, B. divergens and B. caballi [105]. The mode of action of 
imidocarb is not fully understood, however, two mechanisms have 
been  proposed:  interference  with  the  production  or  use  of 
polyamines  [117],  or  the  prevention  of  entry  of  inositol  into  the 
parasitized  erythrocyte,  producing  starvation  of  the  protozoan 
[118].  Imidocarb  is  associated  with  residue  problems;  several 
studies have showed that imidocarb is retained in edible tissues of 
ruminants  for  long  periods  after  treatment [103,  118-121].  Some 
authors  reported high concentrations of  imidocarb in the milk of 
ewes during the  first day of treatment, reflecting its  fast passage 
through  the  blood-milk  barrier  and  a  high  storage  due  to  the 
trapping by ionization of the basic drug in milk [122]. The same 
authors  found  a  low  mammary  elimination  of  the  drug  in  goats, 
probably  associated  with  strong  binding  to  mammary  tissue. 
Therefore,  the  use  of  imidocarb  in  food  producing  animals  has 
caused some concern. Imidocarb retained in edible tissues has been 
related with the resistance of the drug to biotransformation proce-
sses, as reported in in vitro studies on cattle and in vivo studies on 
sheep  [119,  123]  due  to  a  strong  binding of  the  drug  to  nuclear 
components, causing the formation of large deposits principally in 
hepatocytes, in which imidocarb is accumulated in the cell nucleus 
[120].  
3.1.2. Diminazene Aceturate 
Diminazene  aceturate  (4,4´(azoamino)  dibenzamidine)  is  an 
aromatic  diamidine,  derived  from  Surfen  (bis-2-methyl-4-amino-
quinolyl-6-carbamide) (Fig. 3). It is marketed as a diaceturate salt 
in  a  concentration  of  45%,  in  combination  with  the  stabilizer 
antipyrine  (1´2-dihydro-1´5-dimethyl-2-phenyl-3h-pyrazone-3-
one),  in  a  concentration  of  55%,  which  is  added  because  of  the 
short stability of the diminazene in water [124, 125]. Diminazene 
aceturate is the most used anti-trypanosomal agent [126] and it has 
also been used in the treatment of bovine babesiosis. Diminazene 
binds irreversibly to double-stranded DNA, in the groove between 
complementary strands, via  specific interaction with sites rich in 
adenine-thymine base pairs [127-129]. The type of binding between 
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kinetoplastid DNA (kDNA), which impairs kinetoplast replication 
and  function  [130].  Moreover,  diminazene  inhibits  the 
mitochondrial  topoisomerase  II  [128].  Diminazene  aceturate  is 
effective against B. bigemina, but less effective against B. bovis and 
B.  divergens  [105].  Diminazene  aceturate  consists  of  an  organic 
base and organic acid but once dissolved in water, it dissociates. It 
is usually given by intra-muscular injection at doses of 3-5 mg/kg 
[105].  It  has  been  observed  that  the  occurrence  of  relapse, 
infectious premunity or complete sterile immunity of Babesia, has a 
dose correlation in splenectomised calves [131].  
3.2. Novel Anti-Babesia Drugs  
3.2.1. Triclosan 
Triclosan is a chlorinate aromatic compound (2’,4’,4’-tricloro-
2’-hydroxyphenil  ether),  member  of  a  class  of  synthetic  2-
hydroxydiphenylethers, and exhibits broad-spectrum antimicrobial 
activity  [132]  (Fig.  3).  It  is  widely  used  as  a  component  of 
deodorant soaps, dermatologic  and topical  skin preparations, oral 
rinses, and toothpastes, among others [133]. Triclosan has shown to 
be  effective  against  ammonia-producing  bacteria,  yeast, 
dermatophytes,  and  certain  resident  bacteria  in  the  human  skin 
including  both  Gram-positive  and  the  Gram-negative  types. 
Parasitic  protozoa  must  either  acquire  lipids  from  their  host  or 
synthesize lipids de novo to produce the new cell membrane during 
cell replication. Inhibiting the ability to synthesize new membrane 
prevents  the  parasite  from  increasing  in  surface  area,  thereby 
halting cell proliferation and disease progression [134]. Triclosan 
has demonstrated an inhibitory effect on the growth of Plasmodium 
falciparum,  Toxoplasma  gondii,  Theileria  parva,  Trypanosoma 
brucei  and  Perkinsus  marinus  in  in  vitro  studies,  and  in  in  vivo 
studies with P. berghei in a mouse model [134-138]. The mode of 
action of  triclosan has been associated with the inhibition of the 
enoyl-acyl  carrier  protein  (ACP)  reductase  (FabI),  a  fatty  acid 
synthase  (FAS) located  in the apicoplast of  P.  falciparum  [136]. 
FabI reduces the α, β-unsaturated double bonds of the fatty acids 
bound  to  the  ACP  in  an  NADH  or  NADPH  dependent 
reaction[139].  NAD+  is  the  preferred  co-factor  for  the  P. 
falciparum  FabI  enzyme.  Triclosan  directly  binds  to  FabI, 
increasing its affinity for the oxidized form of the co-factor NAD+, 
and  thus  locking  up  the  enzyme  in  its  NAD-bound  form.  This 
leaves no room for NADH binding, which is an essential step, thus 
bringing  FAS  and  hence  the  cell  growth  to  a  halt  [139].  X-ray 
structural analysis of FabI bound to triclosan demonstrated that the 
critical binding element of triclosan is the phenol moiety [140]. The 
fatty acid synthesis pathway is crucial to parasite survival as a result 
of a key role in membrane construction and energy reduction [141]. 
P.  falciparum  synthesizes  fatty  acids  with  the  type  II  fatty  acid 
system  (FAS  II),  however  the  type  I  fatty  acid  system  (FAS  I) 
present  in animals and humans is absent; this is in contrast with 
other  apicomplexan  parasites  such  as  Cryptosporidium  parvum, 
which has no plastid and T. gondii, which possesses both fatty acid 
systems  [142].  In  relation  with  Babesia,  the  inhibitory  effect  of 
triclosan on the growth of parasites has been reported in in vitro 
culture studies [111]. The growth of B. bovis and B. bigemina were 
inhibited at a triclosan concentration of 100 µg/ml, while B. caballi 
and  T.  equi  were  susceptible  to  a  dose  as  low  as  50  µg/ml.  In 
addition,  triclosan  prevented  parasite  re-growth  in  subsequent 
subcultures and all stages of the parasite appeared to be affected by 
the drug. No  toxicity  against host cells was found following the 
addition  of  triclosan  [111].  However,  the  mode  of  action  of 
triclosan in Babesia has not been described yet; the inhibition effect 
of  triclosan  is  on  the  fatty  acid  system  but  genome-sequencing 
studies  indicated  that  Babesia  bovis  doesn’t  have  the  fatty  acid 
synthesis pathway in its apicoplast [4], suggesting the presence of a 
FabI homologue in the chromosomal genome or the existence of 
another  mode of  action.  Triclosan may also  act in Babesia upon 
cellular  membranes,  perturbing  their  physical  properties  and 
disrupting  their  function  as  it  has  been  observed  for  T.  brucei, 
where triclosan acts  through other mechanisms not  involving the 
enoyl-ACP  reductase  [138].  Therefore,  additional  studies  of  the 
mode of drug action and evaluation of the chemotherapeutic effect 
of triclosan are clearly needed on bovine Babesia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Chemical structures of current and novel drugs against babesiosis.  
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3.2.2. Nerolidol 
Nerolidol, also known as peruviol, is a sesquiterpene present in 
essential  oils  of  several  plants  (Fig.  3).  It  is  food-flavoring 
compound, approved by the U.S. Food and Drug Administration 
[110, 143]. It has shown an anti-neoplastic activity, and it has been 
tested as a skin penetration enhancer for the transdermal delivery of 
therapeutic  drugs  [143,  144].  Nerolidol  has  also  shown 
leishmanicidal and anti-malarial activities, due to interference with 
isoprenoid  biosynthesis  of  the  parasites  [110,  143,  145].  The 
apicoplast of apicomplexan parasites has synthesis pathways such 
as fatty acid biosynthesis and isoprenoid biosynthetic pathways [4]. 
The  synthesis  of  isopentenyl  diphosphate  (IPP),  the  universal 
isoprenoid precursor, has long been assumed to proceed exclusively 
via the acetate/mevalonate (MVA) ubiquitous pathway, a pathway 
that  is  absent  from  malaria  parasites  [110,  146].  In  Leishmania 
amazonensis,  it  has  been  shown  that  nerolidol  inhibits  the 
isoprenoid  biosynthesis  since  it  reduces  the  incorporation  of 
mevalonic  acid  (MVA)  or  acetic  acid  precursors  into  dolichol, 
ergosterol  and  ubiquinone  in  treated  promastigotes  due  to  the 
blockage of an early step in the mevalonate pathway [143]. In the 
case of P. falciparum, it has been reported that nerolidol interferes 
with the isoprenoid biosynthetic pathway of the apicoplast, leading 
to interference with the biosynthesis of dolichols, with the isoprenic 
chain  of  ubiquinones,  and  with  protein  isoprenylation  of  the 
parasites [147]. In the case of Babesia parasites, it has been shown 
in vitro that nerolidol can inhibit  the growth of B. bovis,  and B. 
bigemina  at  10  µM  and  B.  ovata,  and  B.  caballi  at  25  µM;  the 
parasite growth is completely suppressed at 50 µM for B. bigemina, 
and  at  75  µM  for  B.  bovis,  B.  ovata,  and  B.  caballi  [110].  The 
calculated IC50 values of nerolidol on the third day of culture for 
the growth of B. bovis, B. bigemina, B. ovata, and B. caballi were 
21±1,  29.6±3,  26.9±2,  and  23.1±1  µM,  respectively.  The 
mechanism  of  inhibition  of  Babesia  parasites  is  unknown, 
nevertheless,  it  is  known  that  B.  bovis  has  an  active  isoprenoid 
pathway in its apicoplast, which is similar to that of P. falciparum 
and T. parva [4]. Probably Babesia parasites have the same mode of 
action than  P. falciparum. More studies with neroridol should be 
done to elucidate its mechanism of action, and its effect in in vivo 
experiments. 
3.2.3. Artesunate 
Artemisinin and its derivatives such as artesunate, artemether, 
arteether and dihydroartemisinin are the most common anti-malarial 
drugs available around the world [108]. They are extracted from a 
herb  called  quinghao  (Artemisia  annua—sweet  Annie,  sweet 
wormwood), which has been used in the Chinese medicine as an 
antimalarial  herb  [148].  Artemisinin  is  a  sesquiterpene  triozane 
lactone,  contains  an  endoperoxide  bridge  (Fig.  3)  essential  for 
antimalaria activity, and has a broad specificity against Plasmodium 
developmental  stages,  including  activity  throughout  the  asexual 
blood stages and sexual gametocyte stages [149-151]. Artemisinin 
has  low  solubility  either  in  water  or  oil,  and  it  can  only  be 
administered orally. Several semi-synthetic artemisinin derivatives 
have been developed to improve solubility in both, oil and water, 
for oral, parenteral and intra-rectal routes [149]. These derivatives 
are the most important  classes of anti-malarial drugs  and have  a 
strong  impact  on  modern  malaria  treatment  regimens  [152]. 
Artesunate is a water soluble half-ester succinate derivative, it is the 
most common derivative and it is very effective in the treatment of 
severe  malaria  cases  [150].  The  major  mode  of  action  of 
artemisinins  is  by  inhibiting  a  mammalian  Ca
2+  transporting 
ATPase  (SERCA-sarcoplamic/endoplasmic  reticulum  Ca
2+ 
ATPase).  SERCA’s  role  is  to  reduce  cystolic  free  calcium  by 
actively  concentrating  Ca
2+  into  membrane  bounds  vacuoles,  an 
activity critical to cell survival. Then, artemisinins act by inhibiting 
PfATP6 (a SERCA orthologue enzyme) outside the food vacuole 
after activation by iron in P. falciparum [150]. Moreover it has been 
showed  that  artemisinins  targets  are  the  calcium  dependent 
ATPases  in  Toxoplasma  gondii  [153].  However  other  studies 
showed that the SERCA inhibition of artemisinins is not clear and 
it is not the only mode of action of artemisinins [150]. Artemisinins 
can accumulate within neutral lipids and cause parasite membrane 
damage [154]. Also, over-expression of  enzymes associated with 
oxidative  stress,  such  as  catalase,  superoxide  dismutase  II, 
thioredoxin  reductase, γ -glutamylcysteine  synthase  and  several 
members  of  the  glutathione-S-transferase  (GST)  family,  have 
shown to reduce susceptibility of tumor cells to artemisinins [155-
157]. Artesunate has shown a growth inhibitory effect on B. caballi, 
with doses of 1.0 µg/ml, in in vitro cultures. However, artesunate is 
able to destroy Theileria equi but unable to destroy B. caballi [158]. 
Artesunate  inhibits  the  growth  of  B.  bovis  and  B.  gibsoni,  at 
concentrations  equal  to  or  greater  than  2.6  µM  by  day  3  post-
treatment  in  a  dose-dependent  manner.  Artesunate  was  also 
effective in the treatment of mice infected with B. microti at doses 
equal to, or greater than 10 mg/kg of body weight on days 8–10 
post-infection without side effects, suggesting that artesunate could 
be a potential drug for Babesia infection [108].  
3.2.4. Epoxomicin 
Epoxomicin belongs to a family of α´, β´-epoxyketone natural 
products characterized by a linear peptide structure [159] (Fig. 3). 
Epoxomicin was initially isolated from an Actinomycetes strain and 
it  is  a  potent  proteasome  inhibitor  [160].  The  proteasome,  a 
prototypic  T1  threonine-peptidase  multi-subunit  complex  plays  a 
key  role  in  endogenous  protein  turnover.  Epoxomicin  covalently 
binds  the  LMP7,  X,  Z  and  MECL1  catalytic  β  subunits  of  the 
proteasome, resulting in inhibition of three of its known proteolytic 
activities,  primarily  the  chymotrypsin-like  activity  although,  the 
trypsin-like activity and the peptidyl-glutamyl peptide hydrolyzing 
(PGPH)  activity  also  can  be  inhibited  [160].  These  inhibitory 
effects  cause  cell  death  by  promoting  the  accumulation  of 
ubiquitinated proteins within the cytoplasm [160, 161]. Proteasome 
inhibitors  like  epoxomicin  have  been  proposed  as  anti-protozoa 
drugs. In the case of apicomplexan parasites, epoxomicin inhibits 
the  growth  of  the  organisms  because  it  blocks  the  catalytically 
active proteasomal subunits[162]. For example, the inhibitory effect 
of epoxomicin has been shown in Plasmodium falciparum, where 
parasites
  throughout  the  asexual,  sexual,  and  mosquito  midgut 
stages were  effectively killed [163, 164]. Epoxomicin has shown 
inhibitory  effects  on  the  in  vitro  growth  of  bovine  and  equine 
Babesia  parasites  and  in  vivo  growth  of  Babesia  microti  [161]. 
Babesia bovis was  significantly  inhibited by 10 nM  epoxomicin, 
while a 5 nM epoxomicin treatment inhibited the growth of Babesia 
bigemina,  Babesia  ovata,  Babesia  caballi,  and  Theileria  equi. 
Moreover, in the presence of 50 nM epoxomicin, the growth of B. 
bigemina and T. equi was completely suppressed. An epoxomicin 
concentration of 100 nM was needed to  completely suppress the 
growth  of  B.  bovis,  B.  ovata,  and  B.  caballi.  Furthermore, 
combinations of epoxomicin with diminazene aceturate potentiated 
its inhibitory effect in in vitro cell cultures. Additional studies are 
required to corroborate whether epoxomicin acts in Babesia species 
inhibiting  the  proteasome  activity  as  in  malaria  parasites.  An 
interesting observation is that epoxomicin effectively inhibits NF-
κβ-mediated  proinflammatory  signaling  and  inhibits  in  vivo 
inflammation [160]. Some Babesia species like B bovis or B. canis 
cause disease characterized by a systemic inflammatory response 
[165, 166]. The effect of epoxomicin on this response must also be 
evaluated since a babesiacidal drug with anti-inflammatory effects 
should be desirable for the treatment of the disease caused by these 
species. 
3.2.5. Gossypol 
Gossypol  is  a  polyphenolic  yellow  pigment  (1,1’,6,6’,7,7’-
hexahydroxy-5,5’-diisopropyl-3,3‘dimethyl  [2,2’-binaphthalene] 
8,8‘-dicar-boxaldehyde) (Fig. 3), found naturally in pigment glands 
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Gossypiurn [167, 168]. It is a natural toxin that protects the plant 
from insect damage. Species and varieties of cotton plants differ in 
concentrations of gossypol present in the seed [169]. Gossypol has 
been  described  as  an  inhibitor  of  the  l-lactate  dehydrogenase  in 
Plasmodium falciparum (pfLHD) [170]. The pfLDH is essential for 
the anaerobic phase of parasite growth and it provides energy to the 
parasite by catalyzing the lactate from piruvate, which is the end 
product  of  glucose  degradation,  using  nicotinamide  adenine 
dinucleotide  (NAD+)  or  its  reduced  form  (NADH)  as  a  cofactor 
[171, 172]. The l-lactate is considered as a prominent product of the 
transition  phase  from  aerobic  to  anaerobic  metabolism  and  it  is 
known  that  in  P.  falciparum,  pfLHD  plays  important  roles  in 
regulating glycolysis (Embden–Meyerhof pathway) and balancing 
the  parasitic  reduced/oxidized  state  [172].  The  most  advanced 
targets of antimalarial structure-based drug design is pfLDH, and 
the researchers has been focused in finding pfLDH inhibitors, such 
as  gossypol  derivatives  [170].  Furthermore,  the  LDHs  of 
Toxoplasma gondii (tgLDH1 and tgLDH2) have been suggested as 
drug targets for enzyme inhibitors such as gossypol [173]. In the 
case of Babesia parasites, a novel Babesia bovis cDNA clone was 
characterized and genetic analysis showed that it contained an open 
reading frame of 993 bp, which was considered to encode a B. bovis 
l-lactate  dehydrogenase  (BbLHD),  having  high  amino  acid 
identities  to  the  LDHs  of  other  protozoans  such  as  Plasmodium 
falciparum and Toxoplasma gondii [174]. Also, native BbLDH was 
expressed  in  the  cytoplasm  and  the  membrane  of  infected 
erythrocytes,  suggesting  the  possibility  that  the  BbLDH  might 
spontaneously  escape  the  parasitic  body  and  partially  imitate  the 
function  of  the  host  LDH,  which  is  essential  for  the  anaerobic 
glycolysis  pathway  of  the  host  red  blood  cells,  exchanging  to  a 
suitable  environment  for  parasitic  survival.  However,  the  exact 
mode of action of BbLDH has not been elucidated. The inhibition 
activity of gossypol on the growth of in vitro Babesia bovis cultures 
was 100µM, which represents an IC50 value of 50 µM [174]. This 
suggests  that  gossypol  can  be  a  babesiadae  drug,  however,  non-
ruminant and pre-ruminant animals are particularly sensitive to the 
toxic  effects  of  gossypol,  and  in  many  non-ruminant  species,  it 
causes  infertility  in  males  as  well  [169].  In  pregnant  cows,  no 
effects  of  gossypol  on  a  superovulation  response  or  embryo 
development were observed [175]. Therefore more research should 
be  done  on  the  efficacy  of  gossypol  and  its  derivatives  against 
Babesia as well as on the effects in the vertebrate host. 
3.2.6. Atovaquone 
Atovaquone (1,4-hydroxynaphthoquinone) (Fig. 3) is  an  anti-
protozoal  compound  that  has  broad-spectrum  activity  against 
apicomplexan  parasites  [176]  such  as  Plasmodium  spp., 
Pneumocystis carinii,  Toxoplasma gondii  and Babesia spp. [177, 
178]. The mode of action of atovaquone against protozoa parasites 
is  by  inhibiting  the  rate  of  oxygen  consumption  [179].  In  most 
eukaryotes  the  electron  transport  chain  is  central  to  the  energy 
metabolism of metabolically active cells. In higher organisms the 
electron  transport  chain  is  composed  by  four  membrane-enzyme 
complexes  in  the  mitochondrial  inner  membrane:  NADH-ubiqui-
none oxidoreductase (Complex I), succinate: ubiquinone oxidoredu-
ctase  (complex  II),  ubiquinol:cytochrome  c  oxidoreductase 
(Complex  III  or  cytochrome  bc1),  and  cytochrome  c  oxidase 
(complex IV or cytochrome aa3), with ubiquinone (coenzyme Q) 
and  cytochrome  c  functioning  as  electron  carriers  between  the 
complexes [180]. In many apicomplexan parasites complex I of the 
electron transport. However, they have the activity of complex II, 
III and IV, but reducing equivalents from NADH can be donated 
directly to ubiquinone in the mithocondrial membrane by a single-
subunit NADH dehydrogenase [181]. Atovaquone acts as an active 
protozoal  ubiquinone  analogue,  which  is  a  mitochondrial  protein 
involved  in  the  electron  transport  chain  [177].  Ubiquinone  (also 
called coenzyme Q) is an integral component of electron transport 
system in aerobic respiration. Ubiquinone transfers electrons from  
 
the primary substrates to the oxidase system at the same time that it 
transfers  protons  to  the  outside  of  the  mitochondrial  membrane. 
Ubiquinone  accepts  electrons  from  dehydrogenase  enzymes  and 
passes  them  to  electron  transport  cytochromes.  The  passage  of 
electrons  from  ubiquinone  to  cytochrome  bc1  (complex  III) 
requires binding of coenzyme Q complex III at the Qo cytochrome 
domain  [177].  Atovaquone  binds  the  Qo  cytochrome  domain 
(Complex  III)  and  the  site  of  inhibition  locates  between 
cytochromes b and c1 of this complex with an irreversibly bound to 
a polypeptide with an approximate molecular mass of 11,500 Da 
[182]. Atovaquone inhibited the respiratory chain of rodent malaria 
parasites and caused the collapse of their mitochondrial membrane 
potential in in vivo assays [183].  
Several parasite enzymes linked to the mitochondrial electron 
transport  system  are  inhibited,  such  as  dihydroorotate 
dehydrogenase  (DHOD),  which  catalyzes  the  oxidation  of 
dihydroorotate  to  orotate  and  is  required  for  the  biosynthesis  of 
pyrimidines. Because plasmodia parasites  are unable  to scavenge 
pyrimidines  for  DNA  synthesis  and  they  are  required  to  be 
synthesized de novo, inhibition of DHOD results in parasite death 
[177,  184].  In  Babesia  bovis,  the  mitochondrion  also  helps  to 
synthesize the pyrimidine nucleotides de novo, through the passage 
of electrons by DHOD, which is linked to a respiratory chain via 
ubiquinones [185]. Atovaquone seems to be very efficient against 
B.  divergens  infecting  human  erythrocytes  in  vitro  [106]. 
Atovaquone  plus  azithromycin  have  demonstrated  superiority 
compared  to  clindamycin  and  quinine  in  the  prevention  and 
treatment of experimental babesiosis in hamsters [186, 187]. Also, 
an antibiotic regimen based on a combination of atovaquone and 
azithromycin in humans is generally superior to a combination of 
clindamycin and quinine for the treatment of babesiosis principally 
in immunocompetent adult patients and in others that do not have 
tolerance for clindamycin and quinine [188]. Atovaquone has been 
proved  to  be  effective  against  B.  divergens  in  gerbils  (Meriones 
unguiculatus) [189]. Acute fulminating infections were effectively 
treated with as little as 1.0 mg/kg with increasing effectiveness up 
to 10 mg/kg. Atovaquone has shown to be a new drug to effectively 
inhibit  the  growth  of  Babesia  divergens,  although  the  effect  on 
other Babesia species should be investigated as well as the mode of 
action in the mitochondria. 
3.2.7. New Drugs Under Research  
Recently, the identification of new drug targets for the control 
of babesiosis has been described [190]. Cysteine proteases (CP) are 
therapeutic  targets  of  inhibitors  of  some  apicomplexan  parasites 
[191, 192]. In Babesia, it that been reported that cysteine proteases 
reduce in vitro invasion of erythrocytes and the growth of B. bovis 
[191]. A gene belonging to the C1 family of CP from B. bigemina 
(called  babesipain-1)  was  previously  identified.  A  series  of  new 
artemisinin-dipeptydil vinyl sulfone hybrid molecules were found 
as inhibitors of babesipain-1, being effective on the range of 0.3–30 
µM,  depending  on  the  core-containing  molecule  [190]. 
Furthermore, three cathepsin L-like cysteine proteases (BbiCPL 1–
3),  were  identified  in  the  B.  bigemina  genome  [193].  Recently, 
BbiCPL1  was  cloned  and  expressed  as  a  fusion  protein  and  a 
recombinant  BbiCPL1  was  obtained,  which  has  activity  against 
typical peptide substrates of cysteine proteases [194]. This finding 
will  allow  researchers  to  screen  for  specific  inhibitors  against 
babesiosis in large-scale studies. BbiCPL1 and the B. bovis ortholog 
(named  bovipain-2)  were  immuno-localized  to  an  undefined 
intracellular  organelle  and  to  the  cytoplasm  of  infected 
erythrocytes,  suggesting  that  BbiCPL1  may  have  its  function  in 
host  cytosol  environment  or  in  an  intracellular  organelle  [195]. 
More  research  should  be  done  on  the  molecular  mechanisms  of 
these CP on Babesia spp., as well as other, yet undiscovered drug 
targets for the treatment of babesiosis.  1514    Current Medicinal Chemistry,  2012 Vol. 19, No. 10  Mosqueda et al. 
4. CONCLUSIONS 
Detection  and  treatment  of  babesiosis  are  important  tools  to 
control  babesiosis.  Microscopy  detection  methods  are  still  the 
cheapest  and  fastest  methods  used  to  identify  Babesia  parasites 
although  their  sensitivity  and  specificity  are  limited.  Newer 
immunological methods are being developed and they offer faster, 
more sensitive and more specific options to conventional methods, 
although the direct immunological diagnoses of parasite antigens in 
host tissues are still missing. Detection methods based on nucleic 
acid identification and their amplification are the most sensitive and 
reliable techniques available today; they are fast, very specific and 
although  most  of  them  relay  on  sophisticated  equipment,  new 
methodologies are being developed without the need of expensive 
apparatus.  Importantly,  most  of  those  methodologies  were 
developed  before  the  genomics  and  bioinformatics  era,  which 
leaves ample room for optimization. For years, babesiosis treatment 
has  been  based  on  the  use  of  very  few  drugs  like  imidocarb  or 
diminazene  aceturate.  Recently,  several  pharmacological 
compounds were developed and evaluated, offering new options to 
control  the  disease.  With  the  complete  sequence  of  the  Babesia 
bovis genome and the B. bigemina genome project in progress [4], 
the  post-genomic  era  brings  a  new  light  on  the  development  of 
diagnosis methods and new chemotherapy targets. 
ACKNOWLEDGEMENTS 
This work was partially funded by CONACyT, and PROMEP. 
REFERENCES 
[1]  Ristic, M. In Diseases of Cattle in the Tropics, Firts Edition ed. Ristic, M.; 
McIntyre, I., Eds.; Martinus Nijhoff Publishers: The Hague, 1981; Vol. 6, pp 
443-468. 
[2]  Bock,  R.;  Jackson,  L.;  de  Vos,  A.;  Jorgensen,  W.,  Babesiosis  of  cattle. 
Parasitology, 2004, 129 Suppl, S247-269. 
[3]  Zintl,  A.;  Mulcahy,  G.;  Skerrett,  H.E.;  Taylor,  S.M.;  Gray,  J.S.,  Babesia 
divergens, a bovine blood parasite of veterinary and zoonotic importance. 
Clinical microbiology reviews, 2003, 16, (4), 622-636. 
[4]  Brayton, K.A.; Lau, A.O.; Herndon, D.R.; Hannick, L.; Kappmeyer, L.S.; 
Berens,  S.J.;  Bidwell,  S.L.;  Brown,  W.C.;  Crabtree,  J.;  Fadrosh,  D.; 
Feldblum, T.; Forberger, H.A.; Haas, B.J.; Howell, J.M.; Khouri, H.; Koo, 
H.; Mann, D.J.; Norimine, J.; Paulsen, I.T.; Radune, D.; Ren, Q.; Smith, 
R.K.,  Jr.;  Suarez,  C.E.;  White,  O.;  Wortman,  J.R.;  Knowles,  D.P.,  Jr.; 
McElwain,  T.F.;  Nene,  V.M.,  Genome  sequence  of  Babesia  bovis  and 
comparative  analysis  of  apicomplexan  hemoprotozoa.  PLoS  pathogens, 
2007, 3, (10), 1401-1413. 
[5]  Babes,  V., Sur l' hémoglobinurie bactérienne du boeuf. . C. R. Acad. Sci., 
1888, 107, 692-694. 
[6]  Smith,  T.;  Kilborne,  F.L.,  Investigations  into  the  nature,  causation,  and 
prevention of  Texas or southern cattle fever. Bureau of Animal Industry, 
1893, Bull 1, 85-114. 
[7]  Graham,  O.H.;  Hourrigan,  J.L.,  Eradication  programs  for  the  arthropod 
parasites of livestock. Journal of medical entomology, 1977, 13, (6), 629-
658. 
[8]  Guerrero,  F.D.;  Bendele,  K.G.;  Davey,  R.B.;  George,  J.E.,  Detection  of 
Babesia  bigemina  infection  in  strains  of  Rhipicephalus  (Boophilus) 
microplus collected from outbreaks in south Texas. Veterinary parasitology, 
2007, 145, (1-2), 156-163. 
[9]  Penzhorn,  B.L.,  Babesiosis  of  wild  carnivores  and  ungulates.  Veterinary 
parasitology, 2006, 138, (1-2), 11-21. 
[10]  Perez de Leon, A.A.; Strickman, D.A.; Knowles, D.P.; Fish, D.; Thacker, E.; 
de  la  Fuente,  J.;  Krause,  P.J.;  Wikel,  S.K.;  Miller,  R.S.;  Wagner,  G.G.; 
Almazan, C.; Hillman, R.; Messenger, M.T.; Ugstad, P.O.; Duhaime, R.A.; 
Teel,  P.D.;  Ortega-Santos,  A.;  Hewitt,  D.G.;  Bowers,  E.J.;  Bent,  S.J.; 
Cochran,  M.H.;  McElwain,  T.F.;  Scoles,  G.A.;  Suarez,  C.E.;  Davey,  R.; 
Howell Freeman, J.M.; Lohmeyer, K.; Li, A.Y.; Guerrero, F.D.; Kammlah, 
D.M.; Phillips,  P.; Pound, J.M., One Health approach to identify research 
needs  in  bovine  and  human  babesioses:  workshop  report.  Parasites  & 
vectors, 2010, 3, (1), 36. 
[11]  Mosqueda, J.; Falcon, A.; Antonio Alvarez, J.; Alberto Ramos, J.; Oropeza-
Hernandez, L.F.; Figueroa, J.V., Babesia bigemina sexual stages are induced 
in  vitro  and  are  specifically  recognized  by  antibodies  in  the  midgut  of 
infected Boophilus microplus ticks. International journal for parasitology, 
2004, 34, (11), 1229-1236. 
[12]  Logue,  J.N.  Beyond  the  germ  teory:  the  story  of  Cooper  Curtice.  Texas 
A&M University Press, 1995. 
[13]  Morzaria, S.; Katende, J.; Kairo, A.; Nene, V.; Musoke, A., New methods for 
the diagnosis of Babesia bigemina infection. Memorias do Instituto Oswaldo 
Cruz, 1992, 87 Suppl 3, 201-205. 
[14]  Potgieter, F.T.; Els, H.J., An electron microscopic study of intra-erythrocytic 
stages of Babesia bovis in the brain capillaries of infected splenectomized 
calves. The Onderstepoort journal of veterinary research, 1979, 46, (1), 41-
49. 
[15]  Aikawa,  M.;  Rabbege,  J.;  Uni,  S.;  Ristic,  M.;  Miller,  L.H.,  Structural 
alteration of the membrane of erythrocytes infected with Babesia bovis. The 
American journal of tropical medicine and hygiene, 1985, 34, (1), 45-49. 
[16]  Jacobson, L.S., The South African form of severe and complicated canine 
babesiosis: clinical advances 1994-2004. Veterinary parasitology, 2006, 138, 
(1-2), 126-139. 
[17]  Potgieter, F.T.; Els, H.J., The fine structure of intra-erythrocytic stages of 
Babesia bigemina. The Onderstepoort journal of veterinary research, 1977, 
44, (3), 157-168. 
[18]  Bose, R.; Jorgensen,  W.K.; Dalgliesh, R.J.; Friedhoff, K.T.; de  Vos, A.J., 
Current  state  and  future  trends  in  the diagnosis  of  babesiosis.  Veterinary 
parasitology, 1995, 57, (1-3), 61-74. 
[19]  Bishop, J.P.; Adams, L.G., Combination thin and thick blood films for the 
detection of Babesia parasitemia. American journal of veterinary research, 
1973, 34, (9), 1213-1214. 
[20]  Uilenberg, G., Diagnosis of Babesia argentina infection in cattle using brain 
smears. Australian veterinary journal, 1972, 48, (9), 534. 
[21]  Riek, R.F., The life cycle of Babesia bigemina (Smith & Kilborne, 1893) in 
the tick vector Boophilus microplus (Canestrini). Aust J Agric Res, 1964, 15, 
802-821. 
[22]  Friedhoff,  K.;  Scholtyseck,  E.,  [Fine  structure  of  Babesia  ovis 
(Piroplasmidea)  in  Rhipicephalus  bursa  (Ixodoidea):  transformation  from 
spheroid to vermicule form]. Z Parasitenkd, 1968, 30, (4), 347-359. 
[23]  Friedhoff, K.; Scholtyseck, E., [Fine structure of the merozoites of Babesia 
bigemina in the ovary of Boophilus microplus and Boophilus decoloratus]. Z 
Parasitenkd, 1969, 32, (3), 266-283. 
[24]  Mahoney, D.F.; Mirre, G.B., The selection of larvae of Boophilus microplus 
infected  with  Babesia  bovis  (syn  B  argentina).  Research  in  veterinary 
science, 1977, 23, (1), 126-127. 
[25]  Ristic, M.; Sibinovic, S., Serologic diagnosis of Babesia bigemina infection 
in cattle by the indirect fluorescent antobody test. Res Vet Sci, 1964, 9, 557. 
[26]  Vercammen,  F.;  De  Deken,  R.;  Maes,  L.,  Clinical  and  serological 
observations on experimental infections with Babesia canis and its diagnosis 
using the IFAT. Parasite, 1995, 2, (4), 407-410. 
[27]  Krause,  P.J.;  Telford,  S.R.,  3rd;  Ryan,  R.;  Conrad,  P.A.;  Wilson,  M.; 
Thomford,  J.W.;  Spielman,  A.,  Diagnosis  of  babesiosis:  evaluation  of  a 
serologic test for the detection of Babesia microti antibody. The Journal of 
infectious diseases, 1994, 169, (4), 923-926. 
[28]  Duh,  D.;  Jelovsek,  M.;  Avsic-Zupanc,  T.,  Evaluation  of  an  indirect 
fluorescence  immunoassay  for  the  detection  of  serum  antibodies  against 
Babesia divergens in humans. Parasitology, 2007, 134, (Pt 2), 179-185. 
[29]  Johnston,  L.A.;  Pearson,  R.D.;  Leatch,  G.,  Evaluation  of  an  indirect 
fluorescent antibody test for detecting Babesia argentina infection in cattle. 
Australian veterinary journal, 1973, 49, (8), 373-377. 
[30]  Morzaria,  S.P.;  Brocklesby,  D.W.;  Harradine,  D.L.,  Evaluation  of  the 
indirect fluorescent antibody test for Babesia major and Theileria mutans in 
Britain. The Veterinary record, 1977, 100, (23), 484-487. 
[31]  Burridge,  M.J.;  Kimber,  C.D.;  McHardy,  N.,  Detection  of  antibodies  to 
Babesia  bigemina  in  dried  blood  samples  using  the  indirect  fluorescent 
antibody test. Annals of tropical medicine and parasitology, 1973, 67, (2), 
191-195. 
[32]  Weiland, G., Species-specific serodiagnosis of equine piroplasma infections 
by means of complement fixation test (CFT), immunofluorescence (IIF), and 
enzyme-linked  immunosorbent  assay  (ELISA).  Veterinary  parasitology, 
1986, 20, (1-3), 43-48. 
[33]  Goodger, B.V., Preparation and preliminary assessment of purified antigens 
in  the  passive  haemagglutination  test  for  bovine  babesiosis.  Australian 
veterinary journal, 1971, 47, (6), 251-256. 
[34]  Goff,  W.L.; Jessup, D.A.;  Waldrup, K.A.; Thomford, J.W.; Conrad,  P.A.; 
Boyce,  W.M.;  Gorham,  J.R.;  Wagner,  G.G.,  The  isolation  and  partial 
characterization of a Babesia sp. from desert bighorn sheep (Ovis canadensis 
nelsoni). The Journal of eukaryotic microbiology, 1993, 40, (3), 237-243. 
[35]  Cantu,  A.;  Ortega,  S.J.;  Mosqueda,  J.;  Garcia-Vazquez,  Z.;  Henke,  S.E.; 
George, J.E., Immunologic and molecular identification of Babesia bovis and 
Babesia  bigemina  in  free-ranging  white-tailed  deer  in  northern  Mexico. 
Journal of wildlife diseases, 2007, 43, (3), 504-507. 
[36]  Ramos, C.M.; Cooper, S.M.; Holman, P.J., Molecular and serologic evidence 
for Babesia bovis-like parasites in white-tailed deer (Odocoileus virginianus) 
in south Texas. Veterinary parasitology, 2010, 172, (3-4), 214-220. 
[37]  Bose, R.; Peymann, B., Diagnosis of Babesia caballi infections in horses by 
enzyme-linked  immunosorbent  assay  (ELISA)  and  western  blot. 
International journal for parasitology, 1994, 24, (3), 347-346. 
[38]  Purnell,  R.E.;  Hendry,  D.J.;  Bidwell,  D.E.;  Turp,  P.,  Microplate  enzyme 
linked immunosorbent assay for antibody to Babesia divergens in cattle. The 
Veterinary record, 1976, 99, (6), 102. 
[39]  Waltisbuhl, D.J.; Goodger, B.V.; Wright, I.G.; Commins, M.A.; Mahoney, 
D.F., An enzyme linked immunosorbent assay to diagnose Babesia bovis 
infection in cattle. Parasitology research, 1987, 73, (2), 126-131. Detection and Treatment of Babesiosis  Current Medicinal Chemistry,  2012 Vol. 19, No. 10      1515 
[40]  O'Donoghue,  P.J.;  Friedhoff,  K.T.;  Vizcaino,  O.G.;  Weyreter,  H.,  The 
detection of IgM and IgG antibodies against Babesia bigemina in bovine sera 
using  semi-defined  antigens  in  enzyme  immunoassays.  Veterinary 
parasitology, 1985, 18, (1), 1-12. 
[41]  Bose, R.;  Jacobson, R.H.; Gale, K.R.;  Waltisbuhl, D.J.;  Wright, I.G., An 
improved ELISA for the detection of antibodies against Babesia bovis using 
either a native or a recombinant B. bovis antigen. Parasitology research, 
1990, 76, (8), 648-652. 
[42]  Boonchit, S.; Xuan, X.; Yokoyama, N.; Goff, W.L.; Wagner, G.; Igarashi, I., 
Evaluation  of  an  enzyme-linked  immunosorbent  assay  with  recombinant 
rhoptry-associated protein 1 antigen against Babesia bovis for the detection 
of specific antibodies in cattle. Journal of clinical microbiology, 2002, 40, 
(10), 3771-3775. 
[43]  Fukumoto, S.; Xuan, X.; Nishikawa, Y.; Inoue, N.; Igarashi, I.; Nagasawa, 
H.; Fujisaki, K.; Mikami, T., Identification and expression of a 50-kilodalton 
surface antigen of Babesia gibsoni and evaluation of its diagnostic potential 
in an enzyme-linked immunosorbent assay. Journal of clinical microbiology, 
2001, 39, (7), 2603-2609. 
[44]  Ikadai, H.; Osorio, C.R.; Xuan, X.; Igarashi, I.; Kanemaru, T.; Nagasawa, H.; 
Fujisaki, K.; Suzuki, N.; Mikami, T., Detection of Babesia caballi infection 
by  enzyme-linked  immunosorbent  assay  using  recombinant  48-kDa 
merozoite rhoptry protein. International journal for parasitology, 2000, 30, 
(5), 633-635. 
[45]  Goff, W.L.; Johnson, W.C.; Molloy, J.B.; Jorgensen, W.K.; Waldron, S.J.; 
Figueroa,  J.V.;  Matthee,  O.;  Adams,  D.S.;  McGuire,  T.C.;  Pino,  I.; 
Mosqueda, J.; Palmer, G.H.; Suarez, C.E.; Knowles, D.P.; McElwain, T.F., 
Validation  of  a  competitive  enzyme-linked  immunosorbent  assay  for 
detection  of  Babesia  bigemina  antibodies  in  cattle.  Clinical  and  vaccine 
immunology : CVI, 2008, 15, (9), 1316-1321. 
[46]  Goff,  W.L.; McElwain,  T.F.; Suarez, C.E.; Johnson,  W.C.; Brown,  W.C.; 
Norimine,  J.;  Knowles,  D.P.,  Competitive  enzyme-linked  immunosorbent 
assay based on a rhoptry-associated protein 1 epitope specifically identifies 
Babesia  bovis-infected  cattle.  Clinical  and  diagnostic  laboratory 
immunology, 2003, 10, (1), 38-43. 
[47]  Goff, W.L.; Molloy, J.B.; Johnson, W.C.; Suarez, C.E.; Pino, I.; Rhalem, A.; 
Sahibi,  H.;  Ceci,  L.;  Carelli,  G.;  Adams,  D.S.;  McGuire,  T.C.;  Knowles, 
D.P.;  McElwain,  T.F.,  Validation  of  a  competitive  enzyme-linked 
immunosorbent  assay  for  detection  of  antibodies  against  Babesia  bovis. 
Clinical and vaccine immunology : CVI, 2006, 13, (11), 1212-1216. 
[48]  Kappmeyer, L.S.; Perryman, L.E.; Hines, S.A.; Baszler,  T.V.; Katz,  J.B.; 
Hennager, S.G.; Knowles, D.P., Detection of equine antibodies to babesia 
caballi  by  recombinant  B.  caballi  rhoptry-associated  protein  1  in  a 
competitive-inhibition  enzyme-linked  immunosorbent  assay.  Journal  of 
clinical microbiology, 1999, 37, (7), 2285-2290. 
[49]  Weigl,  B.;  Domingo,  G.;  Labarre,  P.;  Gerlach,  J.,  Towards  non-  and 
minimally instrumented, microfluidics-based diagnostic devices. Lab on a 
chip, 2008, 8, (12), 1999-2014. 
[50]  Wongsrichanalai, C.; Barcus, M.J.; Muth, S.; Sutamihardja, A.; Wernsdorfer, 
W.H., A review of malaria diagnostic tools: microscopy and rapid diagnostic 
test (RDT). The American journal of tropical medicine and hygiene, 2007, 
77, (6 Suppl), 119-127. 
[51]  Luo, Y.; Jia, H.; Terkawi, M.A.; Goo, Y.K.; Kawano, S.; Ooka, H.; Li, Y.; 
Yu, L.; Cao, S.;  Yamagishi, J.; Fujisaki, K.; Nishikawa,  Y.; Saito-Ito, A.; 
Igarashi, I.; Xuan, X., Identification and characterization of a novel secreted 
antigen 1 of Babesia microti and evaluation of its potential use in enzyme-
linked immunosorbent assay and immunochromatographic test. Parasitology 
international, 2011, 60, (2), 119-125. 
[52]  Kim, C.; Alhassan, A.; Verdida, R.A.; Yokoyama, N.; Xuan, X.; Fujisaki, K.; 
Kawazu, S.; Igarashi, I., Development of two immunochromatographic tests 
for the serodiagnosis of bovine babesiosis.  Veterinary parasitology, 2007, 
148, (2), 137-143. 
[53]  Jia, H.; Liao, M.; Lee, E.; Nishikawa, Y.; Inokuma, H.; Ikadai, H.; Matsuu, 
A.; Igarashi, I.; Xuan, X., Development of an immunochromatographic test 
with recombinant BgSA1 for the diagnosis of Babesia gibsoni infection in 
dogs. Parasitology research, 2007, 100, (6), 1381-1384. 
[54]  Verdida, R.A.; Xuan, X.; Fukumoto, S.; Huang, X.; Zhou, J.; Igarashi, I.; 
Claveria,  F.G.;  Nagasawa,  H.,  Development  of  a  practical 
immunochromatographic  test  with  recombinant  P50  for  the  diagnosis  of 
Babesia gibsoni infection in dogs. Parasitology, 2005, 131, (Pt 6), 769-774. 
[55]  Huang,  X.;  Xuan,  X.;  Verdida,  R.A.;  Zhang,  S.;  Yokoyama,  N.;  Xu,  L.; 
Igarashi, I., Immunochromatographic test for simultaneous serodiagnosis of 
Babesia  caballi  and  B.  equi  infections  in  horses.  Clinical  and  vaccine 
immunology : CVI, 2006, 13, (5), 553-555. 
[56]  Kim, C.M.; Blanco, L.B.; Alhassan, A.; Iseki, H.; Yokoyama, N.; Xuan, X.; 
Igarashi,  I.,  Development  of  a  rapid  immunochromatographic  test  for 
simultaneous serodiagnosis of bovine babesioses caused by Babesia bovis 
and  Babesia  bigemina.  The  American  journal  of  tropical  medicine  and 
hygiene, 2008, 78, (1), 117-121. 
[57]  Fernando, S.D.; Karunaweera, N.D.; Fernando, W.P., Evaluation of a rapid 
whole blood immunochromatographic assay for the diagnosis of Plasmodium 
falciparum  and  Plasmodium  vivax  malaria.  The  Ceylon  medical  journal, 
2004, 49, (1), 7-11. 
[58]  McLaughlin,  G.L.;  Edlind,  T.D.;  Ihler,  G.M.,  Detection  of  Babesia  bovis 
using DNA hybridization. The Journal of protozoology, 1986, 33, (1), 125-
128. 
[59]  Buening, G.M.; Barbet, A.; Myler, P.; Mahan, S.; Nene, V.; McGuire, T.C., 
Characterization of a repetitive DNA probe for Babesia bigemina. Veterinary 
parasitology, 1990, 36, (1-2), 11-20. 
[60]  Posnett,  E.S.;  Ambrosio,  R.E.,  DNA  probes  for  the  detection  of  Babesia 
caballi. Parasitology, 1991, 102 Pt 3, 357-365. 
[61]  Figueroa, J.V.; Chieves, L.P.; Byers, P.E.; Frerichs, W.M.; Buening, G.M., 
Evaluation of a DNA-based probe for the detection of cattle experimentally 
infected  with  Babesia  bigemina.  Annals  of  the  New  York  Academy  of 
Sciences, 1992, 653, 131-145. 
[62]  Conrad, P.A.; Thomford, J.W.; Marsh, A.; Telford, S.R., 3rd; Anderson, J.F.; 
Spielman,  A.;  Sabin,  E.A.;  Yamane,  I.;  Persing,  D.H.,  Ribosomal  DNA 
probe for differentiation of Babesia microti and B. gibsoni isolates. Journal 
of clinical microbiology, 1992, 30, (5), 1210-1215. 
[63]  Hodgson,  J.L.;  Stiller,  D.;  Jasmer,  D.P.;  Buening,  G.M.;  Wagner,  G.G.; 
McGuire, T.C., Babesia bigemina: quantitation of infection in nymphal and 
adult Boophilus microplus using a DNA probe. Experimental parasitology, 
1992, 74, (1), 117-126. 
[64]  Ramos,  J.A.;  Alvarez,  J.A.;  Figueroa,  J.V.;  Solis,  J.;  Rodriguez,  R.I.; 
Hernandez,  R.;  Buening,  G.M.;  Vega,  C.A.,  Evaluation  of  a  colorimetric 
Babesia bigemina-DNA probe within an epidemiological survey. Memorias 
do Instituto Oswaldo Cruz, 1992, 87 Suppl 3, 213-217. 
[65]  Fahrimal, Y.; Goff, W.L.; Jasmer, D.P., Detection of Babesia bovis carrier 
cattle by using polymerase chain reaction amplification of parasite DNA. 
Journal of clinical microbiology, 1992, 30, (6), 1374-1379. 
[66]  Figueroa, J.V.; Chieves, L.P.; Johnson, G.S.; Buening, G.M., Detection of 
Babesia  bigemina-infected  carriers  by  polymerase  chain  reaction 
amplification. Journal of clinical microbiology, 1992, 30, (10), 2576-2582. 
[67]  Persing, D.H.; Mathiesen, D.; Marshall, W.F.; Telford, S.R.; Spielman, A.; 
Thomford, J.W.; Conrad, P.A., Detection of Babesia microti by polymerase 
chain reaction. Journal of clinical microbiology, 1992, 30, (8), 2097-2103. 
[68]  Figueroa, J.V.; Chieves, L.P.; Johnson, G.S.; Goff,  W.L.; Buening, G.M., 
Polymerase chain reaction-based diagnostic assay to detect cattle chronically 
infected  with  Babesia  bovis.  Revista  latinoamericana  de  microbiologia, 
1994, 36, (1), 47-55. 
[69]  Sahagun-Ruiz,  A.;  Waghela,  S.D.;  Holman,  P.J.;  Chieves,  L.P.;  Wagner, 
G.G., Biotin-labeled DNA probe in a PCR-based assay increases detection 
sensitivity  for  the  equine  hemoparasite  Babesia  caballi.  Veterinary 
parasitology, 1997, 73, (1-2), 53-63. 
[70]  Petrigh,  R.;  Ruybal,  P.;  Thompson,  C.;  Neumann,  R.;  Moretta,  R.; 
Wilkowsky,  S.;  Draghi,  G.;  Echaide,  I.;  de  Echaide,  S.T.;  Farber,  M., 
Improved molecular tools for detection of Babesia bigemina. Annals of the 
New York Academy of Sciences, 2008, 1149, 155-157. 
[71]  Fukumoto, S.; Xuan, X.; Shigeno, S.; Kimbita, E.; Igarashi, I.; Nagasawa, 
H.; Fujisaki, K.; Mikami, T., Development of a polymerase chain reaction 
method for diagnosing Babesia gibsoni infection in dogs. The Journal of 
veterinary  medical  science  /  the  Japanese  Society  of  Veterinary  Science, 
2001, 63, (9), 977-981. 
[72]  Aktas,  M.;  Altay,  K.;  Dumanli,  N.,  Development  of  a  polymerase  chain 
reaction method for diagnosis of Babesia ovis infection in sheep and goats. 
Veterinary parasitology, 2005, 133, (4), 277-281. 
[73]  Alhassan, A.; Pumidonming, W.; Okamura, M.; Hirata, H.; Battsetseg, B.; 
Fujisaki, K.; Yokoyama, N.; Igarashi, I., Development of a single-round and 
multiplex PCR method for the simultaneous detection of Babesia caballi and 
Babesia equi in horse blood. Veterinary parasitology, 2005, 129, (1-2), 43-
49. 
[74]  Duarte,  S.C.;  Linhares,  G.F.;  Romanowsky,  T.N.;  da  Silveira  Neto,  O.J.; 
Borges, L.M., Assessment of primers designed for the subspecies-specific 
discrimination among Babesia canis canis, Babesia canis vogeli and Babesia 
canis rossi by PCR assay. Veterinary parasitology, 2008, 152, (1-2), 16-20. 
[75]  Saiki,  R.K.;  Chang,  C.A.;  Levenson,  C.H.;  Warren,  T.C.;  Boehm,  C.D.; 
Kazazian, H.H., Jr.; Erlich, H.A., Diagnosis of sickle cell anemia and beta-
thalassemia with enzymatically amplified DNA and nonradioactive allele-
specific oligonucleotide probes. The New England journal of medicine, 1988, 
319, (9), 537-541. 
[76]  Kaufhold,  A.;  Podbielski,  A.;  Baumgarten,  G.;  Blokpoel,  M.;  Top,  J.; 
Schouls,  L.,  Rapid  typing  of  group  A  streptococci  by  the  use  of  DNA 
amplification  and  non-radioactive  allele-specific  oligonucleotide  probes. 
FEMS microbiology letters, 1994, 119, (1-2), 19-25. 
[77]  Rijpkema, S.G.; Molkenboer, M.J.; Schouls, L.M.; Jongejan, F.; Schellekens, 
J.F.,  Simultaneous  detection  and  genotyping  of  three  genomic  groups  of 
Borrelia  burgdorferi  sensu  lato  in  Dutch  Ixodes  ricinus  ticks  by 
characterization of the amplified intergenic spacer region between 5S and 
23S rRNA genes. Journal of clinical microbiology, 1995,  33, (12), 3091-
3095. 
[78]  Criado-Fornelio,  A.,  A  review  of  nucleic-acid-based  diagnostic  tests  for 
Babesia and Theileria, with emphasis on bovine piroplasms. Parassitologia, 
2007, 49 Suppl 1, 39-44. 
[79]  Gubbels, J.M.; de Vos, A.P.; van der Weide, M.; Viseras, J.; Schouls, L.M.; 
de Vries, E.; Jongejan, F., Simultaneous detection of bovine Theileria and 
Babesia  species  by  reverse  line  blot  hybridization.  Journal  of  clinical 
microbiology, 1999, 37, (6), 1782-1789. 
[80]  Almeria,  S.;  Castella,  J.;  Ferrer,  D.;  Gutierrez,  J.F.;  Estrada-Pena,  A.; 
Sparagano, O., Reverse line blot hybridization used to identify hemoprotozoa 
in Minorcan cattle. Annals of the New York Academy of Sciences, 2002, 969, 
78-82. 1516    Current Medicinal Chemistry,  2012 Vol. 19, No. 10  Mosqueda et al. 
[81]  Butler, C.M.; Nijhof, A.M.; van der Kolk, J.H.; de Haseth, O.B.; Taoufik, A.; 
Jongejan,  F.;  Houwers,  D.J.,  Repeated  high  dose  imidocarb  dipropionate 
treatment did not eliminate Babesia caballi from naturally infected horses as 
determined by PCR-reverse line blot hybridization. Veterinary parasitology, 
2008, 151, (2-4), 320-322. 
[82]  Niu, Q.; Luo, J.; Guan, G.; Liu, Z.; Ma, M.; Liu, A.; Gao, J.; Ren, Q.; Li, Y.; 
Qiu, J.; Yin, H., Differentiation of two ovine Babesia based on the ribosomal 
DNA  internal  transcribed  spacer  (ITS)  sequences.  Experimental 
parasitology, 2009, 121, (1), 64-68. 
[83]  Schnittger,  L.;  Yin,  H.;  Qi,  B.;  Gubbels,  M.J.;  Beyer,  D.;  Niemann,  S.; 
Jongejan,  F.;  Ahmed,  J.S.,  Simultaneous  detection  and  differentiation  of 
Theileria  and  Babesia parasites  infecting  small  ruminants  by  reverse  line 
blotting. Parasitology research, 2004, 92, (3), 189-196. 
[84]  Chiang,  P.W.;  Song,  W.J.;  Wu,  K.Y.;  Korenberg,  J.R.;  Fogel,  E.J.;  Van 
Keuren, M.L.; Lashkari, D.; Kurnit, D.M., Use of a fluorescent-PCR reaction 
to  detect  genomic  sequence  copy  number  and  transcriptional  abundance. 
Genome research, 1996, 6, (10), 1013-1026. 
[85]  Suarez, C.E.; Palmer, G.H.; Florin-Christensen, M.; Hines, S.A.; Hotzel, I.; 
McElwain,  T.F.,  Organization,  transcription,  and  expression  of  rhoptry 
associated protein genes in the Babesia bigemina rap-1 locus. Molecular and 
biochemical parasitology, 2003, 127, (2), 101-112. 
[86]  Matsuu,  A.;  Ono,  S.;  Ikadai,  H.;  Uchide,  T.;  Imamura,  S.;  Onuma,  M.; 
Okano, S.; Higuchi, S., Development of a SYBR green real-time polymerase 
chain  reaction  assay  for  quantitative  detection  of  Babesia  gibsoni  (Asian 
genotype)  DNA.  Journal  of  veterinary  diagnostic  investigation  :  official 
publication  of  the  American  Association  of  Veterinary  Laboratory 
Diagnosticians, Inc, 2005, 17, (6), 569-573. 
[87]  Buling, A.; Criado-Fornelio, A.; Asenzo, G.; Benitez, D.; Barba-Carretero, 
J.C.; Florin-Christensen, M., A quantitative PCR assay for the detection and 
quantification of Babesia bovis and B. bigemina. Veterinary parasitology, 
2007, 147, (1-2), 16-25. 
[88]  Kim,  C.;  Iseki,  H.;  Herbas,  M.S.;  Yokoyama,  N.;  Suzuki,  H.;  Xuan,  X.; 
Fujisaki,  K.;  Igarashi,  I.,  Development  of  TaqMan-based  real-time  PCR 
assays for diagnostic detection of Babesia bovis and Babesia bigemina. The 
American journal of tropical medicine and hygiene, 2007, 77, (5), 837-841. 
[89]  Bhoora,  R.;  Quan,  M.;  Franssen,  L.;  Butler,  C.M.;  van  der  Kolk,  J.H.; 
Guthrie, A.J.; Zweygarth, E.; Jongejan, F.; Collins, N.E., Development and 
evaluation of real-time PCR assays for the quantitative detection of Babesia 
caballi and Theileria equi infections in horses from South Africa. Veterinary 
parasitology, 2010, 168, (3-4), 201-211. 
[90]  Peleg, O.; Baneth, G.; Eyal, O.; Inbar, J.; Harrus, S., Use of chimeric DNA-
RNA  primers  in  quantitative  PCR  for  detection  of  Ehrlichia  canis  and 
Babesia  canis.  Applied  and  environmental  microbiology,  2009,  75,  (19), 
6393-6398. 
[91]  Ramos, C.A.; Araujo, F.R.; Souza, II; Bacanelli, G.; Luiz, H.L.; Russi, L.S.; 
Oliveira,  R.H.;  Soares,  C.O.;  Rosinha,  G.M.;  Alves,  L.C.,  Real-time 
polymerase chain reaction based on msa2c gene for detection of Babesia 
bovis. Veterinary parasitology, 2011, 176, (1), 79-83. 
[92]  He, L.; Feng, H.H.; Zhang, Q.L.; Zhang, W.J.; Khan, M.K.; Hu, M.; Zhou, 
Y.Q.; Zhao, J., Development and Evaluation of Real-Time Pcr Assay for the 
Detection  of  Babesia  Orientalis  in  Water  Buffalo  (Bubalus  Bubalis, 
Linnaeus, 1758). The Journal of parasitology, 2011. 
[93]  Espy, M.J.; Uhl, J.R.; Sloan, L.M.; Buckwalter, S.P.; Jones, M.F.;  Vetter, 
E.A.;  Yao,  J.D.;  Wengenack,  N.L.;  Rosenblatt,  J.E.;  Cockerill,  F.R.,  3rd; 
Smith, T.F., Real-time PCR in clinical microbiology: applications for routine 
laboratory testing. Clinical microbiology reviews, 2006, 19, (1), 165-256. 
[94]  Notomi,  T.;  Okayama,  H.;  Masubuchi,  H.;  Yonekawa,  T.;  Watanabe,  K.; 
Amino,  N.;  Hase,  T.,  Loop-mediated  isothermal  amplification  of  DNA. 
Nucleic acids research, 2000, 28, (12), E63. 
[95]  Mori, Y.; Nagamine, K.; Tomita, N.; Notomi, T., Detection of loop-mediated 
isothermal  amplification  reaction  by  turbidity  derived  from  magnesium 
pyrophosphate  formation.  Biochemical  and  biophysical  research 
communications, 2001, 289, (1), 150-154. 
[96]  Goto,  M.;  Honda,  E.;  Ogura,  A.;  Nomoto,  A.;  Hanaki,  K.,  Colorimetric 
detection  of  loop-mediated  isothermal  amplification  reaction  by  using 
hydroxy naphthol blue. BioTechniques, 2009, 46, (3), 167-172. 
[97]  Ikadai,  H.;  Tanaka,  H.;  Shibahara,  N.;  Matsuu,  A.;  Uechi,  M.;  Itoh,  N.; 
Oshiro,  S.;  Kudo,  N.;  Igarashi,  I.;  Oyamada,  T.,  Molecular  evidence  of 
infections  with  Babesia  gibsoni  parasites  in  Japan  and  evaluation  of  the 
diagnostic  potential  of  a  loop-mediated  isothermal  amplification  method. 
Journal of clinical microbiology, 2004, 42, (6), 2465-2469. 
[98]  Alhassan, A.; Thekisoe, O.M.; Yokoyama, N.; Inoue, N.; Motloang, M.Y.; 
Mbati, P.A.; Yin, H.; Katayama,  Y.; Anzai, T.; Sugimoto, C.; Igarashi, I., 
Development of loop-mediated isothermal amplification (LAMP) method for 
diagnosis of equine piroplasmosis. Veterinary parasitology, 2007, 143, (2), 
155-160. 
[99]  Iseki, H.; Alhassan, A.; Ohta, N.; Thekisoe, O.M.; Yokoyama, N.; Inoue, N.; 
Nambota,  A.;  Yasuda,  J.;  Igarashi,  I.,  Development  of  a  multiplex  loop-
mediated isothermal amplification (mLAMP) method for the simultaneous 
detection of bovine Babesia parasites. Journal of microbiological methods, 
2007, 71, (3), 281-287. 
[100]  Muller,  H.;  Aysul,  N.;  Liu,  Z.;  Salih,  D.A.;  Karagenc,  T.;  Beyer,  D.; 
Kullmann, B.; Ahmed, J.S.; Seitzer, U., Development of a loop-mediated 
isothermal amplification (LAMP) assay for rapid diagnosis of Babesia canis 
infections. Transboundary and emerging diseases, 2010, 57, (1-2), 63-65. 
[101]  He, L.; Zhou, Y.Q.; Oosthuizen, M.C.; Zhao, J.L., Loop-mediated isothermal 
amplification  (LAMP)  detection  of  Babesia  orientalis  in  water  buffalo 
(Bubalus babalis, Linnaeus, 1758) in China. Veterinary parasitology, 2009, 
165, (1-2), 36-40. 
[102]  Guan, G.; Chauvin, A.; Luo, J.; Inoue, N.; Moreau, E.; Liu, Z.; Gao, J.; 
Thekisoe,  O.M.;  Ma,  M.;  Liu,  A.;  Dang,  Z.;  Liu,  J.;  Ren,  Q.;  Jin,  Y.; 
Sugimoto, C.; Yin, H., The development and evaluation of a loop-mediated 
isothermal  amplification  (LAMP)  method  for  detection  of  Babesia  spp. 
infective to sheep and goats in China. Experimental parasitology, 2008, 120, 
(1), 39-44. 
[103]  Suarez,  C.E.;  Noh,  S.,  Emerging  perspectives  in  the  research  of  bovine 
babesiosis and anaplasmosis. Veterinary parasitology, 2011, 180, (1-2), 109-
125. 
[104]  Rodriguez,  R.I.;  Trees,  A.J.,  In  vitro  responsiveness  of  Babesia  bovis  to 
imidocarb dipropionate and the selection of a drug-adapted line. Veterinary 
parasitology, 1996, 62, (1-2), 35-41. 
[105]  Kuttler, K.L. In Babesiosis. Ristic, M.; Keire, J.P., Eds.; Academic Press: 
New York, 1981, pp 25-63. 
[106]  Vial,  H.J.;  Gorenflot,  A.,  Chemotherapy  against  babesiosis.  Veterinary 
parasitology, 2006, 138, (1-2), 147-160. 
[107]  Food  Security  and  Public  Health.  Institute  for  Internal  Cooperation  in 
Animal  Biologics.  Bovine  Babesiosis.  http://www.cfsph.iastate.edu/ICAB/ 
(Acessed December 15, 2011). 
[108]  Goo, Y.K.; Terkawi, M.A.; Jia, H.; Aboge, G.O.; Ooka, H.; Nelson, B.; Kim, 
S.;  Sunaga,  F.;  Namikawa,  K.;  Igarashi,  I.;  Nishikawa,  Y.;  Xuan,  X., 
Artesunate, a potential drug for treatment of Babesia infection. Parasitology 
international, 2010, 59, (3), 481-486. 
[109]  Yeruham,  I.;  Pipano,  E.;  Davidson,  M.,  A  field  strain  of  Babesia  bovis 
apparently resistant to amicarbalide isethionate. Tropical animal health and 
production, 1985, 17, (1), 29-30. 
[110]  AbouLaila, M.; Sivakumar, T.; Yokoyama, N.; Igarashi, I., Inhibitory effect 
of  terpene  nerolidol  on  the  growth  of  Babesia  parasites.  Parasitology 
international, 2010, 59, (2), 278-282. 
[111]  Bork, S.; Yokoyama, N.; Matsuo, T.; Claveria, F.G.; Fujisaki, K.; Igarashi, 
I.,  Growth  inhibitory  effect  of  triclosan  on  equine  and  bovine  Babesia 
parasites. The American journal of tropical medicine and hygiene, 2003, 68, 
(3), 334-340. 
[112]  Gohil, S.; Kats, L.M.; Sturm, A.; Cooke, B.M., Recent insights into alteration 
of  red  blood  cells  by  Babesia  bovis:  moovin'  forward.  Trends  in 
parasitology, 2010, 26, (12), 591-599. 
[113]  Wilson,  R.J.;  Williamson,  D.H.,  Extrachromosomal  DNA  in  the 
Apicomplexa. Microbiol Mol Biol Rev, 1997, 61, (1), 1-16. 
[114]  Fichera,  M.E.;  Roos,  D.S.,  A  plastid  organelle  as  a  drug  target  in 
apicomplexan parasites. Nature, 1997, 390, (6658), 407-409. 
[115]  Kuttler,  K.L.,  Pharmacotherapeutics  of  drugs  used  in  treatment  of 
anaplasmosis and babesiosis. Journal of the American Veterinary Medical 
Association, 1980, 176, (10 Spec No), 1103-1108. 
[116]  EMEA IMIDOCARB SUMMARY REPORT (2); London, May, 2001; pp 1-6. 
[117]  Bacchi,  C.J.;  Nathan,  H.C.;  Hutner,  S.H.;  Duch,  D.S.;  Nichol,  C.A., 
Prevention  by  polyamines  of  the  curative  effect  of  amicarbalide  and 
imidocarb for Trypanosoma brucei infections in mice. Biochem Pharmacol, 
1981, 30, (8), 883-886. 
[118]  McHardy, N.; Woollon, R.M.; Clampitt, R.B.; James, J.A.; Crawley, R.J., 
Efficacy, toxicity and metabolism of imidocarb dipropionate in the treatment 
of Babesia ovis infection in sheep. Research in veterinary science, 1986, 41, 
(1), 14-20. 
[119]  Coldham, N.G.; Moore, A.S.; Dave, M.; Graham, P.J.; Sivapathasundaram, 
S.; Lake, B.G.; Sauer, M.J., Imidocarb residues in edible bovine tissues and 
in vitro assessment of imidocarb metabolism and cytotoxicity. Drug Metab 
Dispos, 1995, 23, (4), 501-505. 
[120]  Moore,  A.S.;  Coldham,  N.G.;  Sauer,  M.J.,  A  cellular  mechanism  for 
imidocarb retention in edible bovine tissues. Toxicol Lett, 1996, 87, (2-3), 
61-68. 
[121]  Coldham, N.G.; Moore, A.S.; Sivapathasundaram, S.; Sauer, M.J., Imidocarb 
depletion from cattle liver and mechanism of retention in isolated bovine 
hepatocytes. Analyst, 1994, 119, (12), 2549-2552. 
[122]  Belloli, C.; Lai, O.R.; Ormas, P.; Zizzadoro, C.; Sasso, G.; Crescenzo, G., 
Pharmacokinetics  and  mammary  elimination  of  imidocarb  in  sheep  and 
goats. J Dairy Sci, 2006, 89, (7), 2465-2472. 
[123]  Aliu,  Y.O.;  Davis,  R.H.,  Jr.;  Camp,  B.J.;  Kuttler,  K.L.,  Absorption, 
distribution, and excretion of imidocarb dipropionate in sheep. Am J Vet Res, 
1977, 38, (12), 2001-2007. 
[124]  Jensch, H., Uber neu typen von Guanylverbindungen. Med. Chem., 1958, 6, 
134-169. 
[125]  Fairclough, R. In Proc. 9
th Meeting of the International Scientific Council for 
Trypanosomiasis Research; Commision for Technical Cooperation in Africa 
, Lagos, CCTA Pub.No. 88: Conakrt, Guinera, 1962, pp 81-86. 
[126]  Peregrine, A.S., Chemotherapy and delivery systems: haemoparasites.  Vet 
Parasitol, 1994, 54, (1-3), 223-248. 
[127]  Gresh, N.; Pullman, B., A theoretical study of the nonintercalative binding of 
berenil and stilbamidine to double-stranded (dA-dT)n oligomers. Molecular 
pharmacology, 1984, 25, (3), 452-458. 
[128]  Peregrine, A.S.; Mamman, M., Pharmacology of diminazene: a review. Acta 
Trop, 1993, 54, (3-4), 185-203. 
 Detection and Treatment of Babesiosis  Current Medicinal Chemistry,  2012 Vol. 19, No. 10      1517 
[129]  Hu,  S.H.;  Weisz,  K.;  James,  T.L.;  Shafer,  R.H.,  H-NMR  studies  on 
d(GCTTAAGC)2  and  its  complex  with  berenil.  European  journal  of 
biochemistry / FEBS, 1992, 204, (1), 31-38. 
[130]  James, D.M.; Giles, H.M. In Pharmacology and usage. Sons, J.W., Ed.: New 
York, 1985. 
[131]  Riley,  J.F.,  The  chemotherapy  of  babesiosis  infections.  Ann  Trop  Med 
Parasitol, 1957, 51, 38-49. 
[132]  EPA, U.S. Triclosan facts. (MARCH, 2010),  
[133]  Beeson, J.G.; Winstanley, P.A.; McFadden, G.I.; Brown, G.V., New agents 
to combat malaria. Nat Med, 2001, 7, (2), 149-150. 
[134]  Lund, E.D.; Soudant,  P.;  Chu,  F.L.; Harvey, E.;  Bolton, S.;  Flowers, A., 
Effects of triclosan on growth, viability and fatty acid synthesis of the oyster 
protozoan parasite Perkinsus marinus. Dis Aquat Organ, 2005, 67, (3), 217-
224. 
[135]  McLeod, R.; Muench, S.P.; Rafferty, J.B.; Kyle, D.E.; Mui, E.J.; Kirisits, 
M.J.; Mack, D.G.; Roberts, C.W.; Samuel, B.U.; Lyons, R.E.; Dorris, M.; 
Milhous,  W.K.; Rice, D.W., Triclosan inhibits the growth of Plasmodium 
falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I. Int J 
Parasitol, 2001, 31, (2), 109-113. 
[136]  Surolia, N.; Surolia, A., Triclosan offers protection against blood stages of 
malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat 
Med, 2001, 7, (2), 167-173. 
[137]  Lizundia, R.; Werling, D.; Langsley, G.; Ralph, S.A., Theileria apicoplast as 
a  target  for  chemotherapy.  Antimicrob  Agents  Chemother,  2009,  53,  (3), 
1213-1217. 
[138]  Paul,  K.S.;  Bacchi,  C.J.;  Englund,  P.T.,  Multiple  triclosan  targets  in 
Trypanosoma brucei. Eukaryot Cell, 2004, 3, (4), 855-861. 
[139]  Rao,  S.P.;  Surolia,  A.;  Surolia,  N.,  Triclosan:  a  shot  in  the  arm  for 
antimalarial chemotherapy. Mol Cell Biochem, 2003, 253, (1-2), 55-63. 
[140]  Freundlich, J.S.;  Wang,  F.;  Tsai, H.C.; Kuo, M.; Shieh, H.M.; Anderson, 
J.W.; Nkrumah, L.J.; Valderramos, J.C.; Yu, M.; Kumar, T.R.; Valderramos, 
S.G.;  Jacobs,  W.R.,  Jr.;  Schiehser,  G.A.;  Jacobus,  D.P.;  Fidock,  D.A.; 
Sacchettini, J.C., X-ray structural analysis of Plasmodium falciparum enoyl 
acyl  carrier  protein  reductase  as  a  pathway  toward  the  optimization  of 
triclosan antimalarial efficacy. J Biol Chem, 2007, 282, (35), 25436-25444. 
[141]  Freundlich, J.S.;  Yu, M.; Lucumi, E.; Kuo, M.; Tsai, H.C.;  Valderramos, 
J.C.;  Karagyozov,  L.;  Jacobs,  W.R.,  Jr.;  Schiehser,  G.A.;  Fidock,  D.A.; 
Jacobus, D.P.; Sacchettini, J.C., Synthesis and biological activity of diaryl 
ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 2'-
substituted triclosan derivatives. Bioorg Med Chem Lett, 2006, 16, (8), 2163-
2169. 
[142]  Grellier, P.; Depoix, D.; Schrevel, J.; Florent, I., Discovery of new targets for 
antimalarial chemotherapy. Parasite, 2008, 15, (3), 219-225. 
[143]  Arruda, D.C.; D'Alexandri, F.L.; Katzin, A.M.; Uliana, S.R., Antileishmanial 
activity of the terpene nerolidol. Antimicrob Agents Chemother, 2005, 49, 
(5), 1679-1687. 
[144]  Yamane, M.A.; Williams, A.C.; Barry, B.W., Terpene penetration enhancers 
in propylene glycol/water co-solvent systems: effectiveness and mechanism 
of action. J Pharm Pharmacol, 1995, 47, (12A), 978-989. 
[145]  Lopes, N.P.; Kato, M.J.; Andrade, E.H.; Maia, J.G.; Yoshida, M.; Planchart, 
A.R.; Katzin, A.M., Antimalarial use of volatile oil from leaves of Virola 
surinamensis (Rol.) Warb. by Waiapi Amazon Indians. J Ethnopharmacol, 
1999, 67, (3), 313-319. 
[146]  Jomaa, H.; Wiesner, J.; Sanderbrand, S.; Altincicek, B.;  Weidemeyer, C.; 
Hintz, M.; Turbachova, I.; Eberl, M.; Zeidler, J.; Lichtenthaler, H.K.; Soldati, 
D.;  Beck,  E.,  Inhibitors  of  the  nonmevalonate  pathway  of  isoprenoid 
biosynthesis as antimalarial drugs. Science, 1999, 285, (5433), 1573-1576. 
[147]  Rodrigues  Goulart,  H.;  Kimura,  E.A.;  Peres,  V.J.;  Couto,  A.S.;  Aquino 
Duarte, F.A.; Katzin, A.M., Terpenes arrest parasite development and inhibit 
biosynthesis of isoprenoids in Plasmodium falciparum. Antimicrob Agents 
Chemother, 2004, 48, (7), 2502-2509. 
[148]  Klayman,  D.L.;  Lin,  A.J.;  Acton,  N.;  Scovill,  J.P.;  Hoch,  J.M.;  Milhous, 
W.K.; Theoharides, A.D.; Dobek, A.S., Isolation of artemisinin (qinghaosu) 
from Artemisia annua growing in the United States. J Nat Prod, 1984, 47, 
(4), 715-717. 
[149]  Golenser, J.; Waknine, J.H.; Krugliak, M.; Hunt, N.H.; Grau, G.E., Current 
perspectives on the mechanism of action of artemisinins. Int J Parasitol, 
2006, 36, (14), 1427-1441. 
[150]  O´Neill, P.M.; Barton, V.E.; Ward, S.A., The molecular mechanism of action 
of artemisin-the debate continue. Molecules, 2010, 15, 1705-1721. 
[151]  Kumar, N.; Zheng, H., Stage-specific gametocytocidal effect in vitro of the 
antimalaria drug qinghaosu on Plasmodium falciparum. Parasitol Res, 1990, 
76, (3), 214-218. 
[152]  Krishna, S.; Uhlemann, A.C.; Haynes, R.K., Artemisinins: mechanisms of 
action and potential for resistance. Drug Resist Updat, 2004, 7, (4-5), 233-
244. 
[153]  Jung, M.; Kim, H.; Nam, K.Y.; No, K.T., Three-dimensional structure of 
Plasmodium falciparum Ca2+-ATPase(PfATP6) and docking of artemisinin 
derivatives  to  PfATP6.  Bioorganic  &amp;  Medicinal  Chemistry  Letters, 
2005, 15, (12), 2994-2997. 
[154]  Hartwig, C.L.; Rosenthal, A.S.; D'Angelo, J.; Griffin, C.E.; Posner, G.H.; 
Cooper,  R.A.,  Accumulation  of  artemisinin  trioxane  derivatives  within 
neutral lipids of Plasmodium falciparum malaria parasites is endoperoxide-
dependent. Biochem Pharmacol, 2009, 77, (3), 322-336. 
 
[155]  Efferth, T.; Briehl, M.M.;  Tome, M.E., Role of antioxidant genes for the 
activity of artesunate against tumor cells. Int J Oncol, 2003, 23, (4), 1231-
1235. 
[156]  Efferth, T., Molecular pharmacology and pharmacogenomics of artemisinin 
and its derivatives in cancer cells. Curr Drug Targets, 2006, 7, (4), 407-421. 
[157]  Romero, M.R.; Serrano, M.A.; Vallejo, M.; Efferth, T.; Alvarez, M.; Marin, 
J.J., Antiviral effect of artemisinin from Artemisia annua against a model 
member of the Flaviviridae family, the bovine viral diarrhoea virus (BVDV). 
Planta Med, 2006, 72, (13), 1169-1174. 
[158]  Nagai, A.; Yokoyama, N.; Matsuo, T.; Bork, S.; Hirata, H.; Xuan, X.; Zhu, 
Y.;  Claveria,  F.G.;  Fujisaki,  K.;  Igarashi,  I.,  Growth-inhibitory  effects  of 
artesunate, pyrimethamine, and pamaquine against Babesia equi and Babesia 
caballi in in vitro cultures. Antimicrobial agents and chemotherapy, 2003, 
47, (2), 800-803. 
[159]  Sin, N.; Kim, K.B.; Elofsson, M.; Meng, L.; Auth, H.; Kwok, B.H.; Crews, 
C.M.,  Total  synthesis  of  the  potent  proteasome  inhibitor  epoxomicin:  a 
useful tool for understanding proteasome biology. Bioorg Med Chem Lett, 
1999, 9, (15), 2283-2288. 
[160]  Meng, L.; Mohan, R.; Kwok,  B.H.; Elofsson, M.; Sin, N.;  Crews,  C.M., 
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo 
antiinflammatory activity. Proc Natl Acad Sci U S A, 1999, 96, (18), 10403-
10408. 
[161]  Aboulaila,  M.;  Nakamura,  K.;  Govind,  Y.;  Yokoyama,  N.;  Igarashi,  I., 
Evaluation of the in vitro growth-inhibitory effect of epoxomicin on Babesia 
parasites. Veterinary parasitology, 2010, 167, (1), 19-27. 
[162]  Mordmuller,  B.;  Fendel,  R.;  Kreidenweiss,  A.;  Gille,  C.;  Hurwitz,  R.; 
Metzger, W.G.; Kun, J.F.; Lamkemeyer, T.; Nordheim, A.; Kremsner, P.G., 
Plasmodia  express  two  threonine-peptidase  complexes  during  asexual 
development. Mol Biochem Parasitol, 2006, 148, (1), 79-85. 
[163]  Czesny,  B.;  Goshu,  S.;  Cook,  J.L.;  Williamson,  K.C.,  The  Proteasome 
Inhibitor Epoxomicin Has Potent Plasmodium falciparum Gametocytocidal 
Activity. Antimicrob. Agents Chemother., 2009, 53, (10), 4080-4085. 
[164]  Kreidenweiss, A.; Kremsner, P.G.; Mordmuller, B., Comprehensive study of 
proteasome inhibitors against Plasmodium falciparum laboratory strains and 
field isolates from Gabon. Malar J, 2008, 7, 187. 
[165]  Schetters,  T.P.; Kleuskens, J.A.;  Van De Crommert, J.; De Leeuw,  P.W.; 
Finizio,  A.L.;  Gorenflot,  A.,  Systemic  inflammatory  responses  in  dogs 
experimentally  infected  with  Babesia  canis;  a  haematological  study. 
Veterinary parasitology, 2009, 162, (1-2), 7-15. 
[166]  Wright,  I.G.;  Goodger,  B.V.;  Clark,  I.A.,  Immunopathophysiology  of 
Babesia bovis and Plasmodium falciparum infections. Parasitol Today, 1988, 
4, (8), 214-218. 
[167]  Quintana,  P.J.;  de  Peyster,  A.;  Klatzke,  S.;  Park,  H.J.,  Gossypol-induced 
DNA breaks in rat lymphocytes are secondary to cytotoxicity. Toxicol Lett, 
2000, 117, (1-2), 85-94. 
[168]  Adams,  R.;  Geissman,  T.A.;  Edwards,  J.D.,  Gossypol,  a  pigment  of 
cottonseed. Chem Rev, 1960, 60, 555-574. 
[169]  Randel,  R.D.;  Chase,  C.C.,  Jr.;  Wyse,  S.J.,  Effects  of  gossypol  and 
cottonseed products on reproduction of mammals. J Anim Sci, 1992, 70, (5), 
1628-1638. 
[170]  Mehlin,  C.,  Structure-based  drug  discovery  for  Plasmodium  falciparum. 
Comb Chem High Throughput Screen, 2005, 8, (1), 5-14. 
[171]  Makler,  M.T.;  Ries,  J.M.;  Williams,  J.A.;  Bancroft,  J.E.;  Piper,  R.C.; 
Gibbins, B.L.; Hinrichs, D.J., Parasite lactate dehydrogenase as an assay for 
Plasmodium falciparum drug sensitivity. Am J Trop Med Hyg, 1993, 48, (6), 
739-741. 
[172]  Dunn,  C.R.;  Banfield,  M.J.;  Barker,  J.J.;  Higham,  C.W.;  Moreton,  K.M.; 
Turgut-Balik,  D.;  Brady,  R.L.;  Holbrook,  J.J.,  The  structure  of  lactate 
dehydrogenase from Plasmodium falciparum reveals a new target for anti-
malarial design. Nat Struct Biol, 1996, 3, (11), 912-915. 
[173]  Dando, C.; Schroeder, E.R.; Hunsaker, L.A.; Deck, L.M.; Royer, R.E.; Zhou, 
X.; Parmley, S.F.; Vander Jagt, D.L., The kinetic properties and sensitivities 
to inhibitors of lactate dehydrogenases (LDH1 and LDH2) from Toxoplasma 
gondii: comparisons with pLDH from Plasmodium falciparum. Mol Biochem 
Parasitol, 2001, 118, (1), 23-32. 
[174]  Bork, S.; Okamura, M.; Boonchit, S.; Hirata, H.; Yokoyama, N.; Igarashi, I., 
Identification  of  Babesia  bovis  L-lactate  dehydrogenase  as  a  potential 
chemotherapeutical  target  against  bovine  babesiosis.  Molecular  and 
biochemical parasitology, 2004, 136, (2), 165-172. 
[175]  Velasquez-Pereira,  J.;  Arechiga,  C.F.;  McDowell,  L.R.;  Hansen,  P.J.; 
Chenoweth, P.J.; Calhoun, M.C.; Risco, C.A.; Batra, T.R.; Williams, S.N.; 
Wilkinson,  N.S.,  Effects  of  gossypol  from  cottonseed  meal  and  dietary 
vitamin E on the reproductive characteristics of superovulated beef heifers. J 
Anim Sci, 2002, 80, (9), 2485-2492. 
[176]  Kessl,  J.J.;  Lange,  B.B.;  Merbitz-Zahradnik,  T.;  Zwicker,  K.;  Hill,  P.; 
Meunier,  B.;  Palsdottir,  H.;  Hunte,  C.;  Meshnick,  S.;  Trumpower,  B.L., 
Molecular basis for atovaquone binding to the cytochrome bc1 complex. J 
Biol Chem, 2003, 278, (33), 31312-31318. 
[177]  Baggish, A.L.; Hill, D.R., Antiparasitic agent atovaquone. Antimicrob Agents 
Chemother, 2002, 46, (5), 1163-1173. 
[178]  Weiss, L.M., Babesiosis in humans: a treatment review. Expert opinion on 
pharmacotherapy, 2002, 3, (8), 1109-1115. 
[179]  Murphy, A.D.; Lang-Unnasch, N., Alternative oxidase inhibitors potentiate 
the  activity  of  atovaquone  against  Plasmodium  falciparum.  Antimicrob 
Agents Chemother, 1999, 43, (3), 651-654. 1518    Current Medicinal Chemistry,  2012 Vol. 19, No. 10  Mosqueda et al. 
[180]  Moyes,  C.D.;  Suarez,  R.K.;  Hochachka,  P.W.;  Ballantyne,  J.S.,  A 
comparison  of  fuel  preferences  of  mitochondria  from  vertebrates  and 
invertebrates. Canadian Journal of Zoology, 1990, 68, (7), 1337-1349. 
[181]  Painter, H.J.; Morrisey, J.M.; Mather, M.W.; Vaidya, A.B., Specific role of 
mitochondrial  electron  transport  in  blood-stage  Plasmodium  falciparum. 
Nature, 2007, 446, (7131), 88-91. 
[182]  Fry,  M.;  Pudney,  M.,  Site  of  action  of  the  antimalarial 
hydroxynaphthoquinone,  2-[trans-4-(4'-chlorophenyl)  cyclohexyl]-3-
hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol, 1992, 43, (7), 
1545-1553. 
[183]  Srivastava,  I.K.;  Rottenberg,  H.;  Vaidya,  A.B.,  Atovaquone,  a  broad 
spectrum antiparasitic drug, collapses mitochondrial membrane potential in a 
malarial parasite. J Biol Chem, 1997, 272, (7), 3961-3966. 
[184]  Hammond,  D.J.;  Burchell,  J.R.;  Pudney,  M.,  Inhibition  of  pyrimidine 
biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-
3-hydroxy-1,4-naphthoquinone in vitro.  Mol Biochem Parasitol, 1985,  14, 
(1), 97-109. 
[185]  Gozar,  M.M.;  O'Sullivan,  W.J.;  Bagnara,  A.S.,  Mitochondrial  function  in 
Babesia bovis. International journal for parasitology, 1992, 22, (2), 165-171. 
[186]  Hughes, W.T.; Oz, H.S., Successful prevention and treatment of babesiosis 
with atovaquone. The Journal of infectious diseases, 1995, 172, (4), 1042-
1046. 
[187]  Wittner, M.; Lederman, J.; Tanowitz, H.B.; Rosenbaum, G.S.; Weiss, L.M., 
Atovaquone in the treatment of Babesia microti infections in hamsters. The 
American journal of tropical medicine and hygiene, 1996, 55, (2), 219-222. 
[188]  Krause, P.J.; Lepore, T.; Sikand, V.K.; Gadbaw, J., Jr.; Burke, G.; Telford, 
S.R., 3rd; Brassard, P.; Pearl, D.; Azlanzadeh, J.; Christianson, D.; McGrath, 
D.;  Spielman,  A.,  Atovaquone  and  azithromycin  for  the  treatment  of 
babesiosis. The New England journal of medicine, 2000, 343, (20), 1454-
1458. 
[189]  Pudney,  M.;  Gray,  J.S.,  Therapeutic  efficacy  of  atovaquone  against  the 
bovine  intraerythrocytic  parasite,  Babesia  divergens.  The  Journal  of 
parasitology, 1997, 83, (2), 307-310. 
[190]  Martins, T.M.; Goncalves, L.M.; Capela, R.; Moreira, R.; do Rosario, V.E.; 
Domingos,  A.,  Effect  of  synthesized  inhibitors  on  babesipain-1,  a  new 
cysteine  protease  from  the  bovine  piroplasm  Babesia  bigemina. 
Transboundary and emerging diseases, 2010, 57, (1-2), 68-69. 
[191]  Okubo, K.; Yokoyama, N.; Govind, Y.; Alhassan, A.; Igarashi, I., Babesia 
bovis: effects of cysteine protease inhibitors on in vitro growth. Experimental 
parasitology, 2007, 117, (2), 214-217. 
[192]  McKerrow, J.H.; Rosenthal, P.J.; Swenerton, R.; Doyle, P., Development of 
protease inhibitors for protozoan infections. Curr Opin Infect Dis, 2008, 21, 
(6), 668-672. 
[193]  Martins, T.M.; do Rosario, V.E.; Domingos, A., Identification of papain-like 
cysteine  proteases  from  the  bovine  piroplasm  Babesia  bigemina  and 
evolutionary  relationship  of  piroplasms  C1  family  of  cysteine  proteases. 
Experimental parasitology, 2011, 127, (1), 184-194. 
[194]  Martins,  T.M.;  do  Rosario,  V.E.;  Domingos,  A.,  Expression  and 
characterization of the Babesia bigemina cysteine protease BbiCPL1. Acta 
Trop, 2012, 121, (1), 1-5. 
[195]  Mesplet,  M.;  Echaide,  I.;  Dominguez,  M.;  Mosqueda,  J.J.;  Suarez,  C.E.; 
Schnittger, L.; Florin-Christensen, M., Bovipain-2, the falcipain-2 ortholog, 
is expressed in intraerythrocytic stages of the tick-transmitted hemoparasite 
Babesia bovis. Parasites & vectors, 2010, 3, 113. 
 
 
Received: October 10, 2011  Revised: October 25, 2011  Accepted: October 26, 2011 
 
 